タイトル:

出版社:

ISBN:

著者:

キーワード:

カテゴリー:

発行年:

～

検索条件をクリア

書籍詳細

未契約

書籍名	新女性医学大系 7 産婦人科薬物療法
出版社	中山書店
発行日	2000-06-30
著者	武谷雄二(総編集) 青野敏博(編集) 麻生武志(編集) 中野仁雄(編集) 野澤志朗(編集) 玉舎輝彦(担当編集)
ISBN	4521542417
ページ数	501
版刷巻号	第1版第1刷
分野	臨床医学：外科産婦人科学
シリーズ	新女性医学大系
閲覧制限	未契約

ピルや各種ホルモン剤等の産婦人科で用いられる薬物のほか、内科、精神科をはじめとするプライマリケアで多用される薬剤についての最新知見を網羅しました。各種薬剤の使用法、薬効・薬理作用・保険適用等も詳述されており、最新の薬物療法事典としても活用できます。

目次

表紙
閲覧
執筆者一覧
閲覧
目次
閲覧
総論女性と薬剤
P.1閲覧
- I 女性における薬物療法
- II 薬物相互作用と薬剤
- III 新薬の開発から臨床応用まで
- IV 生殖機能と薬剤
- V 女性のライフサイクルと薬物療法
産婦人科薬物療法各論
P.75閲覧
- I プライマリケアと薬物療法
- II 産婦人科疾患と薬剤
Glossary
P.465閲覧
索引
P.471閲覧
- 和文索引
- 欧文索引
奥付
閲覧

参考文献

総論女性と薬剤

P.7 掲載の参考文献

1) Martin RM, Biswas PN, et al:Age and sex distribution of suspected adverse drug reactions to newly marketed drugs in general practice in England. Br J Clin Pharmacol 1998;46:505-511

2) Hansen JM, Hallas J, et al:Non-steroidal antiinflammatory drugs and ulcer complications. Scand,J Gastroenterol 1996;31:126-130

3) Nafziger AN, Bertino JS:Sex-related differences in theophylline pharmacokinetics. Eur J Clin Pharmacol 1989;37:97-100

4) Bruguerrole B, Toumi M, et al:Influence of the menstrual cycle on theophylline pharmacokinetics in asthmatics. Eur J Clin Pharmacol 1990;39:59-61

5) Luzier AB, Nawarskas JJ, et al:The effects of gender on adrenergic receptor responsiveness.J Clin Pharmacol 1998;38:618-624

P.16 掲載の参考文献

1) Shimada J, Shiba K, et al:Effect of antacids on absorption of quinolone lomefloxacin. Antimicrob Agents Chemother 1992;36:1219-1224

2) Deppermann KM, Lode H:Fluoroquinolones:Interaction profile during enteral absorption. Drugs 1993;45(suppl):65-72

3) Garrelts JC, Godley PJ, et al:Sucralfate significantly reduces ciprofloxacin concentration in serum. Antimicrob Agents Chemother 1990;34:931-933

4) Nix DE, Watson WA, et al:Effects of aluminum and magnesium antacids and ranitidine on absorption of ciprofloxacin. Clin Pharmacol Ther 1989;46:700-705

5) Noyes M, Polk RE:Norfloxacin and absorption of magnesium-aluminum. Ann Intern Med 1988;109:168-169

6) Sahai J, Gallicano K, et al:Cations in the didanosine tablet reduce ciprofloxacin bioavailability. Clin, Pharmacol Ther 1993;53:292-297

7) Hoffken GK, Borner K, et al:Reduced enteral absorption of ciprofloxacin in the presence of antacids(letter).Eur,J Clin Microbiol 1985:4:345

8) Campbell NRC, Kara M, et al:Norfloxacin interaction with antacids and minerals. Br J Clin Pharmacol 1992;33:115-116

9) Lomaestro BM, Bailie GR:Quinolone-cation interactions:A review. DIPC. Ann Pharmacother 1991;25:1249-1258

10) 澤田泰文, 山田安彦, 伊賀立二: 臨床医のための薬の相互作用とそのマネージメント10. 治療 1998; 80: 2657-2660

11) Jaruratanasirikul S, Kleepkaew A:Influence of an acidic beverage(Coca-Cola)on the absorption of itraconazole. Eur J Clin Pharmacol 1997;52:235-237

12) Hager WD, Fenster P, et al:Digoxin-quinidine interaction.N Engl J Med 1979;300:1238-1241

13) Fromm MF, Kim RB, et al:Inhibition of P-glycoprotein-mediated drug transport:A unifying mechanism to explain the interaction between digoxin and quinidine. Circulation 1999;99:552-557

14) Ducharme MP, Slaughter RL, et al:Itraconazole and hydroxyitraconazole serum concentrations are reduced more tenfold by phenytoin. Clin Pharmacol Ther 1995;58:617-624

15) Periti P, Mazzei T, et al:Pharmacokinetic drug interactions of macrolides. Clin Pharmacokinet 1992;23:106-131

16) Biglin KE, Faraon MS, et al:Drug-induced torsades de pointes:A possible interaction of terfenadine and erythromycin. Ann Pharmacother 1994;28:282
pubmed

17) Brandriss MW, Richardson WS, Barold SS:Erythromycin-induced QT prolongation and polymorphic ventricular tachycardia (torsades de pointes):Case report and review. Clin Infect Dis 1994;18:995-998

18) Pohjola-Sintonen S, Viitasalo M, et al:Itraconazole prevents terfenadine metabolism and increases risk of torsades de pointes ventricular tachycardia. Eur J Clin Pharmacol 1993;45:191-193

19) 廣井正彦: 経口避妊薬の現状と将来. 産婦人科治療 1998; 77: 648. 653

20) Francine ES, Samuel AP:The effect of fluconazole on circulating ethinyl estradiol levels in women taking oral contraceptives. Gygnecology 1999;178:300-304

21) Wysowski DK, Bacsanyi J:Cisapride and fatal arrhythmia. N Engl J Med 1996;335:290-291

22) Upton RA:Pharmacokinetic interactions between theophylline and other medication(part I). Clin Pharmacokinet 1991; 20:66-80
pubmed

23) Upton RA:Pharmacokinetic interactions between theophylline and other medication(part II). Clin Pharmacokinet 19916

24) Sarkar M, Polk RE, et al:In vitro effect of fluoroquinolone on theophylline metabolism in human liver microsomes. Antimicrob Agents Chemother 1990;34:594-599

25) Powell JR, Rogers JF, et al:Inhibition of theophylline clearance by cimetidine but not ranitidine. Arch Intern Med 1984;144:484-486
pubmed

26) Draper AJ, Madan A, Parkinson A:Inhibition of coumarin 7-hydroxylase activity in human liver microsomes. Arch Biochem Biophys 1997;341:47-61

27) 青崎正彦, 大木勝義, ほか: 薬物問相互作用の臨床8 ワルファリン. 治療学 1998; 32: 92-99

28) Kirch W, Hoensch H, Janisch HD:Interactions and non-interactions with ranitidine. Clin Pharmacokinet 1984;9:493-510

29) Bachmann K, Sullivan TJ, et al:Controlled study of the putative interaction between famotidine and theophylline in patients with chronic obstructive pulmonary diseases. J Clin Pharmacol 1995; 35:529-535

30) Shaefer MS, Rossi SJ, et al:Evaluation ofthe pharmacokinetic interaction between cimetidine or famotidine and cyclosporine in healthy men. Ann Pharmacother 1995;29:1088-1091

31) Tailor S, Gupta A, et al:Peripheral edema due to nifedipine-itraconazole interaction:A case report. Arch Dermatol 1996;132:350-352

32) Bailey DG, Malcolm J, et al:Grapefruit juice-drug interactions. Br J Clin Pharmacol 1998;46:101-110

33) Ameer B, Weintraub RA:Drug interactions with grapefruit juice. Clin Pharmacokinet 1997;33:103-121

34) Fuhr U:Drug interactions with grapefruit juice. Extent, probable mechanism and clinical relevance. Drug Saf 1998;18:251-272

35) 厚生省薬務局: 医薬品情報副作用(No.81) エノキサシンとフェンブフェンの相互作用による痙攣発作. 日本醫事新報 1982; 3263: 101-102

36) 堀誠治, 嶋田甚五郎: キノロン薬の安全性-キノロン系薬剤の使い方, 改訂版. 1993; pp37-53, 医薬ジャーナル社, 東京

37) 厚生省薬務局: 医薬品情報副作用(No.98) ニューキノロン系抗菌剤と非ステロイド性消炎鎮痛剤との相互作用(痙攣). 日本醫事新報 1989; 3415: 180-181

P.24 掲載の参考文献

1) 日本公定書協会(編): 新薬臨床評価ガイドライン1999. 1999, 薬事日報社, 東京

2) 日本臨床薬理学会(編): 臨床薬理学. 1996, 医学書院, 東京

3) 横田雅之, 高杉益充(編): 疾患と臨床薬理. 1999, 医薬ジャーナル社, 大阪

4) 臨床評価刊行会: 新GCP/新GPMSP. 臨床評価 1999; 25(補XII)

P.30 掲載の参考文献

1) 藤本孟男: 小児悪性腫瘍. 癌と化学療法 1999; 26(suppl I): 191-198

2) Neequaye JE, Byrne J, Levine PH:Menarche and reproduction after treatment for African Burkitt's lymphoma. BMJ 1991;303:1033
pubmed

3) Koyama H, Wada T, et al:Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer 1977;39:1403-1409

4) 新開奈保子, 椎名美博, 一戸喜兵衛: 絨毛性疾患の化学療法後の妊孕生理について. 日本産科婦人科学会雑誌 1981: 33: 301-304

5) Gradishar WJ, Schilsky RL:Ovarian function following radiation and chemotherapy. Semin Oncol 1989;16:425-436

6) Byrne J, Fears TR, et al:Early menopause in long-term survivors of cancer during adolescence. Am J Obstet Gynecol 1992;166:788-793

7) Newton H:The cryopreservation of ovarian tissue as a strategy for preserving the fertility of cancer patients. Hum Reprod Update 1998;4:237-247

8) Blumenfeld Z, Haim N:Preservation of gonadal damage during cytotoxic therapy. Ann Med 1997;29:199-206

P.35 掲載の参考文献

1) 児童, 生徒の性. 1999年調査. 1999; pp8-13, 学校図書, 東京

2) 黒島淳子: 外陰, 膣の炎症. 臨床婦人科産科 1992; 46: 1299-1302

3) 都もと子, 村田光範, ほか: 特発性早発月経においてdanazol療法を試みた1例. 思春期学 1987; 5: 209-213

4) 田中敏章, 日比逸郎, ほか: 中枢性思春期早発症におけるSuperlong-acting LH-RHアナログ(TAP-144-SR)による6ヶ月間の治療成績. ホルモンと臨床 1992; 40: 835-841

5) 岡田泰助, 川上文, ほか: Long-acting LH-RH analogueを用いた思春期早発症の2女児例. 思春期学1992; 10: 260-267

6) 黒島淳子: 思春期における月経異常. 産婦人科治療 1998; 76: 408-411

7) 黒島淳子: 思春期にみられる出血とその対策産婦人科治療 1997; 75: 147-150

8) 黒島淳子: 月経困難症とその扱い方. 産婦人科治療 1998; 77: 42-46

P.45 掲載の参考文献

1) 玉舎輝彦: 産婦人科領域の特殊性と全般的注意点. 産婦人科薬物療法のすべて. 1996; pp1-11, 金芳堂, 京都

2) 玉舎輝彦: 薬剤の妊娠中投与と催奇形性からみる治療指針. 産婦人科薬物療法のすべて. 1996; pp455-469, 金芳堂, 京都

3) Cunningham FG, MacDonald PC, et al:Drugs and medications. Williams Obstetrics, 20th ed. 1997;pp943-965, Appleton & Lange, Stamford

4) Messing R:Nutritional disorders of the nervous system. Cecil Textbook of Medicine(Bennett JC, Plum F, eds),20th ed.1996;pp2039-2041, WB Saunders, Philadelphia

5) 玉舎輝彦: 妊娠とくすり. 大阪皮膚科専門医会会報 1998; 45: 15-27

P.52 掲載の参考文献

1) Wilson JT, Brown RD, et al:Drugs excretion in human breast milk:Principles, pharmacokinetics and projected consequences. Clin Pharmacokinet 1980;5:1-66

2) 菅原和信, 豊口禎子: 薬剤の母乳への移行. 1984; pp9-23, 南山堂, 東京

3) Kuemmerle HP(ed): Clinical Pharmacology in Pregnancy. Georg Thieme Verlag, Stuttgart [松田静治(監訳): 妊婦と臨床薬理. 1992; pp356-366, 医薬ジャーナル社, 大阪]

4) Wilson JT:Drugs in Breast Milk.1981,ADIS Press, New South Wales

5) 千葉寛: 臨床薬物動態に基づく治療計画法. 妊娠と薬物-母乳への薬物移行. 治療学 1980; 4: 382-391

6) 奥山和男: 薬物療法における新生児の特殊性. 周産期医学 1981; 11: 1393-1397

7) Windorfer A, Gasteiger V:Stillen und Medikamente. Klin Padiatr 1978;190:219-224

8) 松田静治: 母体の抗菌剤療法と胎児, 新生児. 小児科MOOK 53, 1988; pp155-163, 金原出版, 東京

9) 松田静治: 外来における抗菌薬療法の実際産科の立場から-妊婦への投与. JOHNS 1992; 8: 1653-1657

10) 松田静治: 妊婦の化学療法. 感染症学-基礎と臨床(上田泰, ほか編). 1982; pp356-360, メジカルビュー社, 東京

11) 松田静治(編): 妊婦と薬物治療の考え方-投与時の注意と禁忌. 1996; pp111-155, ヴァンメディカル, 東京

12) 佐藤孝道: 妊産婦と薬物-主な注意事項と指導. 周産期医学 1995; 25: 151-154

13) Briggs GG, Freeman RK, Yaffe SJ:Drugs in Pregnancy and Lactation, 4th ed. 1994, Williams & Wilkins, Baltimore

P.63 掲載の参考文献

1) 日本産科婦人科学会(編): 産科婦人科用語解説集, 第2版. 1997, 金原出版, 東京

2) 太田博明: 更年期と骨. ホルモンと臨床 1994; 42: 15-26

3) 日本産科婦人科学会教育・用語委員会報告: 「本邦婦人の閉経・年齢について」に関する委員会提案理由. 日本産科婦人科学会雑誌 1995; 47: 449-451

4) Gregerman RI, Bierman EL:Aging and hormones. Textbook of Endocrinology (Williams RH, ed),6th ed.1974;pp1192-1212, WB Saunders, Philadelphia

5) 赤祖父一知, 荒木克己, 西田悦郎: 加齢に伴う内分泌変化-その他の内分泌系-. 産婦人科MOOK 30, 更年期・老年期の婦人科学. 1985; pp65-73, 金原出版, 東京

6) Block E:Quantitative morphological investigation of the follicular system in women:Variations at different ages. Acta Anat (Basel) 1952;14:108-123

7) Paganini HA, Henderson WW:Estrogen deficiency and risk of Alzheimer's disease in women. Am J Epidemiol 1994;140:256-261

8) 仲川義人: 医薬品相互作用とその留意点. 医薬品相互作用, 第2版. 1998; pp9-21, 医薬ジャーナル社, 大阪

9) Rubio A, Cox C:Sex, age, and alfentanil pharmacokinetics [letter]. Clin Pharmacokinet 1991; 21:81-82

10) Lemmens HJ, Burm AGL, et al:Influence of age on the pharmacokinetics of alfentanil. Clin Pharmacokinet 1990;19:416-422

11) Hunt CM, Westerkam WR, Stave GM:Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol 1992;44:275-283

12) Gustavson LE, Legler UF, Benet LZ:Impairment of prednisolone disposition in women taking oral contraceptives or conjugated estrogens.J Clin Endocrinol Metab 1986;62:234-237
pubmed

13) Greenblatt DJ, Abernethy DR, et al:Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology 1984;61:27-36
pubmed

14) Fleishaker JC, Pearson LK, et al:Hormonal effects on Tirilazad clearance in women:Assessment of the role of CYP3A. J Clin Pharmacol 1999;39:260-267

15) Harris RZ, Tsunoda SM, et al:The effects of menopause and hormone replacement therapies on prednisolone and erythromycin pharmacokinetics. Clin Pharmacol Ther 1996;59:429-435

16) 安原一, 内田英二: 薬理作用・薬物動態の個体差. 臨床薬理学(日本臨床薬理学会, 編), 1996; pp176-187, 医学書院, 東京

17) Gennari C, Agnusdei D, et al:Estrogen preserves a normal intestinal responsiveness to 1,25-dihydroxyvitamin D3 in oophorectomized women. J Clin Endocrinol Metab 1990;71:1288-1293

18) Gustavson LE, Benet LZ:Menopause:Pharmacodynamics and pharmacokinetics. Exp Gerontol 1994;29:437-444

19) Herrmann WM, Beach RC:The psychotropic properties of estrogens. Pharmacopsychiatry 1978; 11:164-176

20) Risch SC, Huey LY, Janowsky DS:Plasma levels of tricyclic antidepressants and clinical efficacy:Review of literature. Part II. J Clin Psychiatry 1979;40:58-69

21) Davidson J, Peltron S:Forms of atypical depression and their response to antidepressant drugs. Psychiatry Res 1986;17:87-95

22) 日本薬剤師会・日本病院薬剤師会(編): 高齢者における薬剤管理指導業務マニュアル. 1998; pp6-20, じほう(薬業時報社), 東京

23) 堀口文, 太田博明: 更年期障害. 臨床成人病 1996; 26: 198-202

24) 太田博明: 更年期と生活習慣病. 毎日ライフ 1999; 30: 54-58

25) 高松潔, 太田博明, ほか: 当科中高年健康維持外来受診者1107名における血清脂質に関する検討-加齢およびホルモン環境の影響について. 日本更年期医学会雑誌 1996; 4: 78-84

26) 高松潔, 太田博明, ほか: 当科中高年健康維持外来受診者の血圧に関する検討. 日本更年期医学会雑誌 1996; 4: 233-239

27) 岡本雅嗣, 弟子丸亮太, ほか: 更年期外来における中高年女性の糖代謝に関する検討. 日本更年期医学会雑誌 1997; 5(suppl): 93

28) 苛原稔: HRTの適応と禁忌. 更年期外来診療プラクティス(青野敏博, 編). 1996; pp53-66, 医学書院, 東京

29) Michnovicz JJ, Galbraith RA:Cimetidine inhibits catechol estrogen metabolism in women. Metabolism 1991;40:170-174

30) Lippert TH, Seeger H, Mueck AO:Metabolism of endogenous estrogens. Estrogens and Antiestrogens I (Oettel M, Schillinger E, eds).1999;pp243-271, Springer-Verlag, Berlin

31) 梅田悦生: イプリフラボン. 常用薬剤医薬品の副作用-禁忌・慎重投与・相互作用への対応. 1996; pp992-993, 南江堂, 東京

P.73 掲載の参考文献

1) Neugarten BL, Moore JW, Lowe JC:Age norms, age constraints and adult socialization. Am J Sociol 1965;70:710-717

2) 鳥羽研二: シンポジウム介護保険と高齢者医療: 施設介護の問題点. 日本老年医学会雑誌 1997; 34(12): 981-986

3) 鳥羽研二, 秋下雅弘, ほか: 薬剤起因性疾患. 日本老年医学会雑誌 1999; 36(3) : 181-185

4) Nagatomo I, Nomaguchi M, Matsumoto K:Sex difference in depression and quality of life in elderly people. Jpn J Psychiat Neurol 1994;48:511-515

5) Wilhelm K, Parker G:Sex differences in lifetime depression rates:Fact or artifact? Psychol Med 1994;24:97-111
pubmed

6) 塩見利明, 岡田啓, ほか: 服薬管理能力スケール(RCS)の作成. 日本老年医学会雑誌 1997; 34: 209-214

7) German PS, Klein LE, et al:Knowledge of and compliance with drug regimen in the elderly. J Am Geriatr Soc 1982;30:568-571

8) Cooper JK, Love DW, Raffoul RR:International prescription nonadherence (noncompliance) by the elderly. J Am Geriatr Soc 1982;30:329-333

9) 上島悦子, 三上洋, ほか: 老年患者の服薬コンプライアンス. 日本老年医学会雑誌 1992; 29: 855-863

10) 秋下雅弘, 大内尉義, ほか: 高齢者の服薬状況および副作用に関する検討. 日本老年医学会雑誌 1995; 32: 178-182

11) 中野重行, 豊澤英子: 高齢者の薬物療法とコンプライアンス. 日本老年医学会雑誌 1999; 36: 173-175

12) 上田慶二: 高齢者薬物療法の問題点. 日本老年医学会雑誌 1998; 35: 589-598

13) 篠原恒樹: 老年者の体内水分量. 代謝 1965; 2: 470

14) 鳥羽研二, 須藤紀子, ほか: 老年者慢性尿路感染症の予後と宿主免疫能. 日本老年医学会雑誌 1993; 30: 487-496

15) Woodhouse KW, Williams F, Mutch E:Phase I drug metabolism in the ageing. Ageing and Gastrointestinal Tract.1988;pp255-265, MTP Press, Lancaster

16) 石崎高志: 高齢者における薬物動態と薬効. 日本老年医学会雑誌 1999; 36: 1168-1172

17) Phillips DP, Christenfeld N, Glynn LM:Increase in US medication-error deaths between 1983 and 1993. Lancet 1998;351:643-644

18) Ferner RE, Anton C:Increase in US medication-error death (letter comment). Lancet 1998; 351:1655-1656

19) Lesar TS, Briceland L, Stein DS:Factors related to errors in medication prescribing. JAMA 1997;277:312-317

20) 大蔵健義: HRTの効果, アルツハイマー病. 臨床婦人科産科 1998; 52: 1359

21) 青野敏博: 臨床医のための女性ホルモン補充療法. 1994; p78, 医学書院, 東京

産婦人科薬物療法各論

P.84 掲載の参考文献

1) 岡崎祐士: 妊娠期および産後の精神障害の病態と予防・治療. 精神科MOOK 11, 身体疾患と精神科障害(原田憲一, 編). 1985; pp148-161, 金原出版, 東京

2) 松島英介: 妊娠, 授乳期の精神薬物療法. 臨床精神医学講座(松下昌明, 総編), 第14巻, 精神科薬物療法. 1999; pp498-515, 中山書店, 東京

3) 田中光芳, 本多裕: 母体に投与した薬剤の新生児に及ぼす影響向精神薬. 周産期医学 1981; 11(10): 1425-1429

4) Aarskog D:Association between maternal intake of diazepam and oral clefts. Lancet 1975;ii (7941):921

5) Safra MJ, Oakley GP Jr:Association between cleft lip with or without cleft palate and prenatal exposure to diazepam. Lancet 1975;ii(7933):478-480
pubmed

6) Saxen I, Saxen L:Association between maternal intake of diazepam and oral clefts. Lancet 1975; ii(7933):498

7) Rosenberg L, Mitchell A, et al:Lack of relation of oral cleft to diazepam use during pregnancy. Engl J Med 1983;309:1282-1285

8) Cree JE, Meyer J, Hailey DM:Diazepam in labour:Its metabolism and effect on the clinical condition and thermogenesis of the newborn. Br J Med, 1973;4:251-255

9) Gillberg C:“Floppy infant syndrome”and maternal diazepam. Lancet 1977;ii(8031):244

10) Atthinarayanan P, Pierig SH, et al:Chlordiazepoxide withdrawal in the neonate. Am J Obstet Gynecol 1976;124:212-213

11) Batnum S:Possible effect of chlordiazepoxide on the fetus. Can Med Assoc J 1969;100:351

12) Mazzi E:Possible neonatal diazepam withdrawal:A case report. Am J Obstet Gynecol 1977; 129:586-587

13) Rementeria JL, Bhatt K:Withdrawal symptoms in neonates from intrauterine exposure to diazepam. J Pediatr 1977;90:123
pubmed

14) Catz CS:Diazepam in breast milk. Drug Ther 1973;3:72-73

15) Freeman R:Limb deformities:Possible association with drugs. Med J Aust 1972;1:606-607

16) McBride WG:Limb deformities associated with iminodibenzyl hydrochloride. Med Aust 1972;1:492
pubmed

17) Barson AJ:Malformed infant. Br Med J 1972;1:45

18) Crombie DL, Pinsent RJ, Fleming D:Imipramine in pregnancy. Br Med J 1972;1:745
pubmed

19) Kuenssberg EV, Knox JDE:Imipramine in pregnancy. Br Med J 1972;2:292

20) Levy L:Imipramine and fetal deformities. Can Med Assoc J 1972;106:1057-1058

21) Morrow AW:Limb deformities associated with iminodibenzyl hydrochloride. Med J Aust 1972;1:658-659

22) Sim M:Imipramine and pregnancy. Br Med J 1972;1:45

23) Eggermont E, Raveschot J, et al:The adverse influence of imipramine on the adaptation of the newborn infant to extrauterine life. Acta Paediatr Belg 1972;26:197-204

24) Ben Musa A, Smith CS:Neonatal effects of maternal clomipramine therapy. Arch Dis Child 1979;54:405

25) O'Brien TE:Excretion of drugs in human milk. Am J Hosp Pharm 1974;31:844-854

26) 筒井末春, 羽仁真奈実, 島田淳子: 不定愁訴とその対策. 産婦人科治療 1998; 77: 21-26

27) 大森健一: 退行期うつ病. 精神科治療学 1994; 9(3): 290-298

28) 融道男: 向精神薬マニュアル. 1998, 医学書院, 東京

P.95 掲載の参考文献

1) 亀山正邦, 亀田治男, ほか(総編集): 今日の治療指針, 第4版. 1999, 医学書院, 東京

2) 国立循環器病センター(編著): 循環器疾患の治療指針, 第2版. 1997, 丸善, 東京

3) 篠山重威, 矢崎義雄(編): 循環器疾患最新の治療 2000-2001. 2000, 南江堂, 東京

4) Medical Practice編集委員会(編): 治療薬ガイド 1999-2000. 1999, 文光堂, 東京

P.100 掲載の参考文献

1) 日本結核病学会非定型抗酸菌症対策委員会: 非定型抗酸菌症の治療に関する見解1998年. 結核 1998; 73: 599-605

2) Management of asthma during pregnancy. National Asthma Education Program, National Heart, Lung, and Blood Institute, National Institutes of Health, NIH Publication No93-3279A. 1993 [井上洋西, 翻訳/監修: 妊娠中の喘息管理ガイドライン(日本語版). 1994, ライフサイエンス出版, 東京より]

3) 工藤宏一郎: 気管支喘息(慢性期). 疾患別最新処方(矢崎義雄, ほか監). 1998; pp222-223, メジカルビュー社, 東京

4) 山田浩和, 森田寛: 気管支拡張薬. 治療薬ガイド(和田攻, ほか編). 1999; pp322-330, 文光堂, 東京

5) 岡本浩明, 渡辺古志郎: 肺癌に対する新しい化学療法薬. Annual Review呼吸器(工藤翔二, ほか編). 1999; pp257-271, 中外医学社, 東京

6) 西村浩一: 肺リンパ脈管筋腫症. 今日の呼吸器疾患治療指針(山本正彦, ほか編). 1992; pp253-254, 医学書院, 東京

7) 太田雅弘, 中野赴: 肺血栓塞栓症. 呼吸器疾患(原澤道美, 監; 北村諭, 編). 1999; pp436-438, 医歯薬出版, 東京

8) 日和田邦男: 胸膜子宮内膜症. 呼吸器症候群(上銘外喜夫, 編). 1994; pp781-784, 日本臨牀社, 大阪

9) 橋元恭士, 工藤翔二; 鎮咳・去痰剤. 治療薬ガイド(和田攻, ほか編). 1999; pp331-338, 文光堂, 東京

P.104 掲載の参考文献

1) 溝口秀昭, 齋藤英彦(編): 血液病学, 第4版. 1996, 医学書院, 東京

2) George JM, Woolf SH, et al:Idiopathic thrombocytopenic purpura:A practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996;88:3-40

3) Bussel JB, Kimberly RP, et al:Intravenous gammaglobulin treatment of chronic idiopathic thrombocytopenic purpura. Blood 1983;62:480-486

4) 倉田義之: ITP症例の妊娠・分娩管理. 臨床血液 1997; 38: 1151-1161

P.109 掲載の参考文献

1) NIH Consensus Conference:Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. JAMA 1994;272 1):65-69
pubmed

2) Raskin JB:Gastrointestinal effects of nonsteroidal anti-inflammatory therapy. Am J Med 1999; 106:3S-12S

3) Scheiman J, Isenberg J:Agents used in the prevention and treatment of nonsteroidal anti-inflammatory drug-associated symptoms and ulcers. Am J Med 1998;105:32S-38S

4) Yoshida H, Shiratori Y, et al:Interferon therapy reduces the risk for hepatocellular carcinoma:National surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 1999;131:174-181

5) Ikeda K, Saitoh S, et al:Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C:A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999;29(4):1124-1130

6) Arase Y, Ikeda K, et al:The long term eflicacy of glycyrrhizin in chronic hepatitis C patients. Cancer 1997;79:1494-1500

7) Oka H, Yamamoto S, et al:Prospective study of chemoprevention of hepatocellular carcinoma with Sho-saiko-to (TJ.9). Cancer 1995;76:743-749

P.113 掲載の参考文献

1) Faro S, Fenner DE:Urinary tract infections, Clin Obstet Gynecol 1998;41:744-754

2) 原岡正志, 田中正利, 熊沢浄一: 尿路感染症の化学療法. 産婦人科治療 1998; 77: 205-208

3) Thuroff JW, Chartier-Kastler E, et al:Medical treatment and medical side effects in urinary incontinence in the elderly. World J Urol 1998;16 (suppl 1):S48-S61

4) 松島正浩, 沢村良勝, ほか: 女性の尿失禁. 日本醫事新報 1998; 3891: 33-36

5) 山口脩, 橋本 : 中高年女性と排尿障害. 産婦人科治療 1998; 77: 192-196

P.120 掲載の参考文献

1) The diabetes control and complications trial research group:The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl Med 1993;329:977-986

2) Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study. Lancet 1998;352:837-853

3) DeFronzo RA:Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999;131:281-303

4) Ashcroft FM, Gribble FM:ATP-sensitive K+ channels and insulin secretion:Their role in health and disease. Diabetologia 1999;42:903-919

5) Iikova H, Glaser B, et al:Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care 1997;20:1353-1356

6) 石田均: 経口抗糖尿病薬選択基準と効果的使用法- α-グルコシダーゼ阻害薬. 日本臨牀 1999; 57: 669-674

7) Levovitz HE:A new oral therapy for diabetes management:Alpha-glucosidase inhibition with acarbose. Clinical Diabetes 1995;13:99-103

8) Sakane N, Yoshida T, et al:Different effects of acarbose and voglibose on serum 1,5-anhydroglucitol concentration. Diabetes Care 1998;21:465
pubmed

9) Hoffman J, Spengler M:Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. Diabetes Care 1994;17:561-566

10) Rosseti L, Giaccan A, DeFronzo RA:Glucose toxicity. Diabetes Care 1990;13:610-630

11) Yoshioka K, Azukari K, et al:The efficacy of voglibose on daily glycemic excursions assessed by the J-index in non-insulin-dependent diabetes mellitus. Horm Metab Res 1997;29:407-408

12) Cusi K, DeFronzo RA:Metformin:A review of its metabolic effects. Diabetes Rev 1998;6:89-131

13) Stang M, Wyscowski DK, Butler-Jones D:Incidence of lactic acidosis in metformin users. Diabetes Care 1999;22:925-927

14) Lehmann JM, Moore LB, et al:An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J Biol Chem 1995;270:12953-12956

15) 兼子俊男, 馬場茂明, ほか: インスリン抵抗性改善薬AD-4833の食事療法のみのインスリン非依存型糖尿病に対する臨床評価. 臨牀と研究 1999; 74: 1491-1514

16) 門脇孝: インスリン抵抗性改善薬. 日本臨牀 2000; 58: 283-290

17) Sakane N, Yoshida T, Kondo M:Glitazones and NIDDM. Lancet 1997;349:952
pubmed

18) Yoshioka K, Yokoo S, et al:Is troglitazone a real indication for obese subjects with impaired glucose tolerance? Diabetes Care 1997;20:1340-1341

19) Fuhlendorff J, Rorsman P, et al:Stimulation of insulin release by repaglinide and glibenclimide involves both common and distinct process. Diabetes 1998;47:345-351

20) 菊池方利: 経口抗糖尿病薬-選択基準と効果的使用法-非SU系インスリン分泌促進薬. 日本臨牀 1999; 57: 702-708

P.127 掲載の参考文献

1) 中村治雄: 原発性高脂血症の疫学. 高脂血症-病態と治療(垂井清一郎, ほか編). 厚生省特定疾患「原発性高脂血症」調査研究班事務局, 1988

2) Gambrell RD, Teran A:Changes in lipids and lipoproteins with long-term estrogen deficiency and hormone replacement therapy. Am J Obstet Gynecol 1991;165:307-317

3) 第4次循環器疾患基礎調査(平成2年11月) の概況. 厚生省保険医療局疾病対策課(平成5年1月). 毎日新聞1993. 2. 4

4) Urabe M, Yamamoto T, et al:Effect of estrogen replacement therapy on hepatic triglyceride lipase. lipoprotein lipase and lipids including apolipoprotein E in climacteric and elderly women. Endocr J 1996;43:737-742

5) Kushwaha RS, Born KM:Effect of estrogen and progesterone on the hepatic cholesterol 7α-hydroxylase activity in ovariectomized baboons. Biochem Biophys Acta 1991;1084:300-302

6) Kovanen PT, Brown MS, Goldstein JL:Increased bindings of low density lipoprotein to liver membranes from rats treated with 17 alpha ethinyl estradiol. J Biol Chem 1979;254:11367-11373

7) 本庄英雄: 更年期・老年期マニュアル. 1993, 金芳堂, 京都

8) Tikkanen MJ, Kuusi T, et al:Variation of postheparin plasma lipase by menstrual cycle. Metabolism 1986;35:99-104

9) Kim HJ, Kalkhoff RK:Changes in lipoprotein composition during the menstrual cycle. Metabolism 1979;28:663-668

10) Lebech AM, Kjaer A:Lipid metabolism and coagulation during the normal menstrual cycle.Horm Metab Res 1989;21:445-448 Barnes RB, Roy S, Lobo RA:Comparison of lipid and androgen levels after conjugated estrogen or depomedroxyprogesterone acetate in postmenopausal women. Obstet Gynecol 1985;66:217-219

11) Barnes RB, Roy S, Lobo RA : Comparison of lipid and androgen levels after conjugated estrogen or depomedroxyprogesterone acetate in postmenopausal women. Obstet Gynecol 1985;66:217-219
pubmed

12) Tikkanen MJ, Nikkila EA, et al:Differential effects of two progestins on plasma high density lipoprotein 2 (HDL2) and postheparin plasma hepatic lipase activity. Atherosclerosis 1981;40:365-369

13) Gronroos M, Lehtonen A:Effect of high dose progestin on serum lipids. Atherosclerosis 1983; 47:101-105

14) Silfverstolpe G, Gustafson A, et al:Lipid metabolic studies in oophorectomized women. Effects of three different progestogens. Acta Obstet Gynecol Scand 1979;88(suppl):89-95

15) Tranquilli AL, Mazzanti AM, et al:Transdermal estradiol and medroxyprogesterone acetate in hormone replacement therapy are both antioxidants. Gynecol Endocrinol 1995;9:137-141

16) Stampfer MJ, Colditz GA, et al:Postmenopausal estrogen therapy and cardiovascular disease. N Engl Med 1991;325:756-762

17) Grady D, Rubin SM, et al:Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-1037

18) National cholesterol education program. Circulation 1994;89:1329-1381

19) 後山尚久: これからの更年期診療実践マニュアル-HRT, 漢方治療の実際を含めて. 1994, 総合医学社, 東京

P.132 掲載の参考文献

1) Ammann P, Rizzoli R, et al:Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency.J Clin Invest 1997;99:1699-1703

2) Lorenzo JA, Naprta A, et al:Mice lacking the type I interleukin-1 receptor do not lose bone mass after ovariectomy. Endocrinology 1998;139:3022-3025
pubmed

3) Poli V, Balena R, et al:Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J 1994;13:1189-1196

4) Riggs BL, Melton III LJ:Involutional osteoporosis. N Engl Med 1986;314:1676-1686

5) Riggs BL, Khosla S, Melton III LJ:A unitary model for involutional osteoporosis:Estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men.J Bone Miner Res 1998;13:763-773

6) Storm T, Thamsborg G, et al:Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis.J Engl Med 1990;322:1265-1271

7) Adachi JD, Bensen WG, et al:Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis.N Engl Med 1997;337:382-387

8) Hosking D, Chilvers CE, et al:Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group.N Engl J Med 1998;338:485-492

9) Liberman UA, Weiss SR, et al:Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporos is Treatment Study Group. N Engl Med 1995;333:1437-1443

10) Cauley JA, Seeley DG, et al:Estrogen replacement therapy and fractures in older women. Study of osteoporotic Fractures Research Group. Ann Intern Med 1995;122:9-16

11) Cauley JA, Seeley DG, et al:Estrogen replacement therapy and mortality among older women. The study of osteoporotic fractures. Arch Intern Med 1997;157:2181-2187

12) Christiansen C, Christensen MS, Transbol I:Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy. Lancet 1981;i:459-461

13) Colditz GA, Hankinson SE, et al:The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. Engl Med 1995;332:1589-1593

14) Tilyard MW, Spears GF, et al:Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med 1992;326:357-362
pubmed

15) Dawson-Hughes B, Harris SS, et al:Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older.N Engl J Med 1997;337:670-678

16) Overgaard K, Hansen MA, et al:Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis:A dose-response study. Br Med J 1992;305:556-561

P.138 掲載の参考文献

1) Cooper DS:Treatment of thyrotoxicosis. Werner and Ingbar's The Thyroid (Braverman LE, Utiger RD, eds),7th ed.1996;pp713-734, Lippincott-Raven, Philadelphia

2) Abuid S, Larsen PR:Triiodothyronine and thyroxine in hyperthyroidism.J Clin Invest 1974; 54:201-208

3) Low LCK, McCruden DC, et al:Intrathyroidal iodine binding rates and plasma methimazole concentrations in hyperthyroid patients on small doses of carbimazole. Br J Clin Pharmacol 1981;12:315-318

4) Shiroozu A, Okumura K, et al:Treatment of hyperthyroidism with a small single daily dose of methimazole. J Clin Endocrinol Metab 1986;63:125-128

5) 田尻淳一, 野口志郎, ほか: 抗甲状腺剤による無顆粒球症, 特に"Normal white blood cell count agranulocytosis"について. 日本内分泌学会雑誌 1993; 69: 1013-1016

6) Yokoyama K, Sato T, et al:Successful treatment of methimazole-induced agranulocytosis by granulocyte colony-stimulating factor. Am J Hematol 1992:40:76-77

7) Momotani N, Ito K, et al:Maternal hyperthyroidism and congenital malformation in the offspring. Clin Endocrinol (Oxf) 1984;20:659-700

8) Haddow JE, Palomaki GE, et al:Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child.N Engl Med 1999;341:549-555

9) 阿部好文: 甲状腺疾患の合併症と対策-妊娠. カレントテラピー 1995; 13: 634-639

10) Lamberts SW, de Lange SA, Stefanko SZ:Adrenocorticotropin-secreting pituitary adenomas originate from the anterior or the intermediate lobe in Cushing's disease:Difrerences in the regulation of hormone secretion.J Clin Endocrinol Metah 1982;54:286-291
pubmed

11) 清水直容: 厚生省昭和56年度「間脳下垂体機能障害」調査研究班報告書(班長熊原雄一). 1982; pp11-18

12) Mercado-Asis LB, Yasuda K, et al:Beneficial effects of high daily dose bromocriptine treatment in Cushing's disease. Endocrinol Jpn 1992;39:385-395

13) Miura K, Aida M, et al:Treatment of Cushing's disease with reserpine and pituitary irradiation. J Clin Endocrinol Metab 1975;41:511-526

14) Murayama M, Yasuda K, et al:Long term follow-up of Cushing's disease treated with reserpine and pituitary irradiation.J Clin Endocrinol Metab 1992;75:935-942

15) 三浦清: Cushing病の内科的治療. 教育講演. 内科診療の進歩. 日本内科学会雑誌 1994; 183: 221-226

16) Krieger DT:Physiopathology of Cushing's disease. Endocr Rev 1983;4:22-43

17) 中野里佳: オペプリム市販後調査のまとめ. 第11回オペプリム研究会議事録. 1996: pp77-87, 日本ヘキストマリオンールセル, 東京

18) 山北宜由, 安田圭吾, 三浦清: 第II編器官別療法, 7. 内分泌系. 4) 副腎癌. d. 化学療法. 癌治療学(上). 日本臨牀 1988; 46(臨時増刊号): 1053-1058

19) Dluhy RG, William GH:Endocrine hypertension. Williams Textbook of Endocrinology(Wilson JD, Foster DW, et al, eds),9th ed.1998;pp729-749, WB Saunders, Philadelphia

20) Yamakita N, Yasuda K, et al:Study on clinical and endocrine characteristics of dexamethasone-suppressible hyperaldosteronism compared with those in primary aldosteronism owing to aldosterone-producing adenoma. Acta Endocrinol 1989;121:334-344

21) 山北宜由, 三浦清: 先天性副腎皮質過形成. 本邦臨床統計集(下巻). 日本臨牀 1993; 51(臨時増刊号): 150-160

22) Loriaux DL:Hirsutism. Clinical Endocrinology Update'95 Syllabus(Dillmann WH;Program Director).1995;pp189-191,The Endocrine Society, Bethesda

23) Elkind-Hirsch KE:Hirsutism. Meet-the-Professor Handout Endo'99. San Diego, The Endocrine Society's 81st Annual Meeting 1999;pp92-97, The Endocrine Society, Bethesda

24) Brazeau P, Vale W, et al:Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 19731;79:77-79

25) 島津章, 井村裕夫, ほか: 末端肥大症及び下垂体巨人症に対する酢酸オクトレオチド(SMS201-995)の長期投与臨床試験成績. 日本内分泌学会雑誌 1992; 68: 89-99

26) Zaoral M, Kolc J, Sorm F:Synthesis of 1-deamino-8-D-gamma-aminobutyrine-vasopressin, 1-deamino-8-lysine-vasopressin. Collec Czech Chem Commun 1967;32:1250-1257

27) 田苗綾子, 清水倉一, 吉出尚: バゾプレッシン誘導体による尿崩症の治療成績-37施設による共同研究. 日本内分泌学会雑誌 1978; 54: 676-691

28) 寺野隆, 吉田尚, 日比逸郎: 中枢性尿崩症に対する酢酸デスモプレッシンスプレー剤(KW-8008) の臨床試験. ホルモンと臨床 1996; 44: 651-661

P.144 掲載の参考文献

1) 鈴木智, 横井則彦, 木下茂: 角膜フリクテンに対する抗生物質点滴大量投与の試み. あたらしい眼科 1998; 15: 1143-1145

2) 島崎潤: ドライアイの定義と診断基準. 眼科 1995; 37: 765-770

P.148 掲載の参考文献

1) 藤田博之, 鈴木衞: 中耳炎検出菌の新しい傾向. 耳鼻咽喉科・頭頸部外科クリニカルトレンドPart2. 1998; pp28-29, 中山書店, 東京

2) 坂倉康夫: 慢性副鼻腔炎の保存的療法の効果と限界. 耳鼻咽喉科・頭頸部外科クリニカルトレンド. 1996; pp140-141, 中山書店, 東京

3) 州崎春海: 慢性副鼻腔炎に対するエリスロマイシン少量長期投与療法. 耳鼻咽喉科・頭頸部外科クリニカルトレンド. 1996; pp136-138, 中山書店, 東京

4) 荻野敏: アレルギー性鼻炎の最近の傾向. 耳鼻咽喉科・頭頸部外科クリニカルトレンド. 1996; pp149-151, 中山書店, 東京

5) 今野昭義, 沼田勉: 妊娠すると鼻アレルギーが悪化したり, 改善したりすることがあるのはなぜか. 耳鼻咽喉科・頭頸部外科クリニカルトレンドPart2. 1998; pp148-149, 中山書店, 東京

6) 馬場廣太郎: アレルギー性鼻炎に対する温熱療法の効果. 耳鼻咽喉科・頭頸部外科クリニカルトレンド. 1996; pp152-153, 中山書店, 東京

7) 切替一郎, 野村恭也: 新耳鼻咽喉科学. 1998; pp465-469, 南山堂, 東京

8) 宮田英雄, 伊藤八次, 白戸弘道: 抗めまい薬. 耳鼻咽喉科・頭頸部外科 1998; 70(増刊5): 151-153

P.153 掲載の参考文献

1) 船橋俊行(編): 妊娠と関係のある皮膚病. 皮膚病診療 1994; 16(6): 485-537

2) 新村眞人, 瀧川雅浩(編): 皮膚疾患最新の治療 1999-2000. 1999, 南江堂, 東京

3) 宮地良樹(編): 皮膚科プライマリケア. 1998, 診断と治療社, 東京

4) 新村眞人, 上出良一(編): 皮膚診療クイックリファレンス. 1998, メジカルビュー社, 東京

P.160 掲載の参考文献

1) Palevsky PM, Bhagrath R, Grrenberg A:Hypernatremia in hospitalized patients. Ann Intern Med 1996;124:197-203

2) Saito T:SIADH and other hyponatremic disorders:Diagnosis and therapeutic problems. Jpn J Nephrol 1996;38:429-434

3) Laureno R, Karp BI:Myelinolysis after correction on hyponatremia. Ann Intern Med 1997; 126:57-62

4) Acker CG, Johnson JP, et al:Hyperkalemia in hospitalized patients:Causes, adequacy of treatment, and results of an attempt to improve physician compliance with published therapy guidelines. Arch Intern Med 1998;158:917-924

5) Bilezikian JP:Management of acute hypercalcemia. N Engl Med 1992;326:1196-1203

6) Motellon JL, Javort Jimenez F, et al:Parathyroid hormone-related protein, parathyroid hormone, and vitamin D in hypercalcemia of malignancy. Clin Chim Acta 2000;290:189-197

7) 橋詰直孝: マグネシウム代謝異常. 日本内科学会雑誌 1997; 86: 1857-1861

8) 福本誠二, 藤田敏郎: 低リン血症と高リン血症. 日本内科学会雑誌 1997; 86: 1851-1856

P.168 掲載の参考文献

1) 堀進悟, 藤島清太郎, ほか: 多臓器不全: MOF, MODS. 救急医学 1998; 22(1): 86-90

2) 相川直樹: ショック. 標準救急医学(日本救急医学会, 編). 1991; pp132-147, 医学書院, 東京

3) 堀進悟: アナフィラキシー. 内科研修医マニュアル(慶應義塾大学医学部内科学教室, 編). 1999; pp91-113, 南江堂, 東京

4) American Heart Association:Adjuncts for airway control ventilation, and oxygenation. Advanced Cardiac Life Support.1997;pp2.1-2.17

5) 堀進悟: ACLS: レジデントに必要な救命処置. 呼吸と循環 1998; 46: 899-905

6) 相川直樹, 堀進悟(編): 救急レジデントマニュアル, 第2版. 1998, 医学書院, 東京

7) Goldharber SZ, Kessler CM, et al:Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. Lancet 1988; ii (8606):293-298

8) 高月誠司, 堀進悟: ショック. Medicina 1998; 35: 130-134

9) 堀進悟: 救急常備薬. 今日の救急治療指針(前川和彦, 相川直樹, 編). 1996; pp757-763, 医学書院, 東京

10) 堀進悟: 救急薬品の投与法. 今日の救急治療指針(前川和彦, 相川直樹, 編). 1996; pp765-767, 医学書院, 東京

11) 宮武諭, 堀進悟: 救急常備薬. Medical Practice 1998; 15(臨時増刊, 図解救急処置・応急処置ガイド): 1002-1009

P.175 掲載の参考文献

1) Conklin KA:Physiologic changes of pregnancy. Obstetric Anesthesia:Principles and Practice (Chesmut DH, ed).1994;pp17-56, Mosby, St Louis

2) Santos AC, Pedersen H, Finster M:Local anesthetics. Obstetric Anesthesia:Principles and Practice(Chestnut DH, ed).1994;pp202-226, Mosby, St Louis

3) Stoelting RK, Miller RD:Basics of Anesthesia. 1984;pp363-387, Churchill Livingstone, New York

4) Ralson DH, Shnider SM, deLormer AA:Effects of equipotent ephedrine, metaraminol, mephentermine and methoxamine on uterine blood flow in the pregnant ewe. Anesthesiology 1974;40:354-370

5) Andersson O. Blomback M, et al:Prediction of changes in levels of haemostatic variables during natural menstrual cycle and ovarian hyperstimulation. Thromb Haemost 1997;77:901-904

6) Briggs GG, Freeman RK Yaffe SJ:Drugs in Pregnancy and Lactation,3rd ed.1990, Williams & Wilkins, Baltimore

7) D'Alessio JG, Ramanathan J:Etfects of maternal anesthesia in the neonate,[Review][95 refs] Semin Perinatol 1998;22:350-362

P.190 掲載の参考文献

1) 玉舎輝彦: 産婦人科感染症. 産婦人科薬物療法のすべて. 1995; pp325-372, pp455-469, 金芳堂, 京都

2) 玉舎輝彦: 産婦人科領域感染症. Pharma Medica 1995; 13: 99-107

3) 三鴨廣繁, 伊藤邦彦, 玉舎輝彦: 産科婦人科領域における嫌気性菌, 特にPrevotella biviaについての臨床的意義に関する研究. 岐阜大学医学部紀要 1994; 42: 230-248

4) 太田美智男: 化学療法. 医系微生物学. 1987; pp73-85, 朝倉書店, 東京

5) Spratt BG:Resistance to antibiotics mediated by target alterations. Science 1994;264:388-393

6) 斧康雄: ペニシリン系. 今日の化学療法 1995; 11(S-｜): 174181

7) 二木芳人, 玉田貞雄: ペニシリン系薬. 抗生物質療法ガイド. 1997; pp96-104, 文光堂, 東京

8) 田村淳: PBPによるβ-ラクタム薬耐性. 化学療法の領域 1996; 12: 1221-1226

9) 武部和夫: セフェム系薬. 抗生物質療法ガイド. 1997; pp105-120, 文光堂, 東京

10) 武部和夫: オキサセフェム系薬. 抗生物質療法ガイド. 1997; pp121-123, 文光堂, 東京

11) 那須勝: 抗生物質の進歩モノバクタム系. 臨床と研究 1992; 69: 689690

12) 後藤純: モノバクタム系薬. 抗生物質療法ガイド. 1997; pp138-140, 文光堂, 東京

13) 後藤純: カルバペネム系薬. 抗生物質療法ガイド. 1997; pp141-144, 文光堂, 東京

14) 賀来満夫: マクロライド系薬. 抗生物質療法ガイド. 1997; pp124-134, 文光堂, 東京

15) 中島良徳: マクロライド薬耐性. 化学療法の領域 1996; 12: 1257-1264

16) Maxwell A:The molecular basis of quinolone action.J Antimicrob Chemother 1992;30:409-414

17) 鈴木幹三: キノロン系薬. 抗生物質療法ガイド. 1997; pp165-171, 文光堂, 東京

18) 井田孝志: アミノ配糖体薬耐性. 化学療法の領域 1996; 12: 1265-1273

19) 和田光一: アミノグリコシド系薬. 抗生物質療法ガイド. 1997; pp145-157, 文光堂, 東京

20) 清水喜八郎, 副島林造: ピペラシリンナトリウム. Jpn J Antibiotics 1994; 47: 469-476

21) 草深祐光, 大林孝彰, ほか: Piperacillinによるamikacinの腎障害軽減作用. 日本腎臓学会誌 1992; 34: 153-162

22) 後藤陽一郎: テトラサイクリン系薬. 抗生物質療法ガイド. 1997; pp151-157, 文光堂, 東京

23) 泉川欣一: リンコマイシン・クリンダマイシン系薬. 抗生物質療法ガイド. 1997; pp135-140, 文光堂, 東京

24) 那須勝, 後藤純: モノバクタム系薬抗生物質Aztreonamに関する基礎的・臨床的研究. Chemotherapy 1985; 33: 493-504

25) 青木ますみ: クロラムフェニコール系薬. 抗生物質療法ガイド. 1997; pp158-161, 文光堂, 東京

26) Wilhelm M:Vancomycin.Mayo Clin Proc 1991;66:1165-1170

27) 日野志郎, 假家悟, ほか: 治療薬使用の手引. 今日の治療指針. 1997; pp1123-1310, 医学書院, 東京(市販薬の調査に用いた)

28) Physicians'desk Reference.1998, Medical Economics, Montvale

P.197 掲載の参考文献

1) Taylor-Robinson D, Thomas BJ:The role of Chlamydia trachomatis in genital-ract and associated disease.J Clin Pathol 1980;33:205-233

2) Oriel JD, Reeve P, et al:Chlamydia infection. Isolation of chlamydia from patlents with non specific genital infection.Br J Dis 1980;48:429-436

3) Richard LS:Chlamydial salpingitis and infertility. Fertil Steril 1982;38:530

4) 野口昌良, 稗田茂雄, ほか: Chlamydia trachomatisによる実験的卵管炎の検討. 日本不妊学会雑誌 1986; 31: 415-420

5) 野口昌良: 実験的卵管炎と周囲癒着に関する研究. 産婦人科マイクロサージャリー学会雑誌 1989; 2: 57-61

6) Patton DL, Moore DE, et al:A comparison of the fallopian tube's response to overt and silent salpingitis. Obstet Gynecol 1989;73:622-630

7) Pal Wolner-Hansen MD:Silent pelvic inflammatory disease:Is it overstated?Obstet Gynecol 1995;86(3):321-325

8) 野口靖之: Chlamydia trachomatisの骨盤内感染による骨盤内癒着と卵管障害に関する基礎的, 臨床的研究. 愛知医科大学医学会雑誌 1998; 26: 59-70

9) Krause DC, Taylor-Robinson D:Mycoplasmas which infect humans. Mycoplasmas. Molecular Biology and Pathogenesis(Maniloff J, McElhaney RN, et al, eds).1992;pp417-444, American Society for Microbiology, Washington DC

10) Deguchi T, Gilroy CB, Taylor-Robinson D:Failure to detect Mycoplasma fermentans, Mycoplasma penetrans, or Mycoplasma pirum in the urethra of patients with acute nongonococcal urethritis, Eur J Clin Micobiol Infect Dis 1996;15:169-171

P.208 掲載の参考文献

1) Elion GB, Furman PA, et al:Selectivity of action of an antiherpetic agent,9-(2-hydroxyethoxy-methyl) guanine., Proc Natl Acad Sci USA 1977;74:5716-5720
pubmed

2) 小松敏昭: 抗ウイルス剤アシクロビル(ゾビラックス(R)) の開発とその薬理作用. 化学療法の領域 1994; 10: 63-70

3) Hashido M, Kawana T: In vitro acyclovir sensitivity of herpes simplex viruses isolated from female genital herpes in Japan. 感染症学雑誌 1988; 62: 141-146

4) Erlich KS, Mills J, et al:Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome.N Engl Med 1989;320:293-296

5) 小野寺一清, 佐々木和也: 抗ウイルス剤. 1991; pp25-31, 学会出版センター, 東京

6) Safrin S, Crumpacker C, et al:A controlled trial comparing foscarnet with vidarabine for cyclovir resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. N Engl J Med 1991;325:551-555

7) Centers for Disease Control and Prevention.1993 Sexually transmitted diseases treatment guidelines. MMWR 1993;42(No. RR-14)
pubmed

8) Centers for Disease Control and Prevention.1998 Guidelines for treatment of sexually transmitted diseases.MMWR 1998;47(No. RR-1):1-111

9) 木村哲: 性感染症(STD)の治療学的展望-後天性免疫不全症候群(エイズ). 化学療法の領域 1999; 15: 129-138

10) Dickover RE, Garratty EM, et al:Identification of levels of maternal HIV-1 RNA associated with risk of perinatal transmission. JAMA 1996;275:599-605

11) 川名尚: 母体への抗菌薬療法の指針. 薬剤の選択と治療の実際妊娠中のウイルス感染症. 周産期医学 1998; 28: 1445-1449

P.214 掲載の参考文献

1) WHO:Drugs Used in Parasitic Diseases. 2nd ed, 1995;p145, WHO, Geneva

2) 大友弘士: 抗原虫薬, 駆虫薬. 治療薬ガイド 1999～2000(和田攻, ほか編). 1999; pp657-664, 文光堂, 東京

3) 大友弘士: 抗寄生虫薬の使い方. Clinical Infection and Chemotherapy 1997: 3(2): 28-35

4) WHO:International Travel and Health. 2000;p108, WHO, Geneva

5) 厚生省熱帯病治療薬の開発研究班: 輸入寄生虫病薬物治療の手引き, 改訂第4版. 1995; p62

6) 加納六郎(編): 節足動物と皮膚疾患. 1999; p313, 東海大学出版会, 東京

7) WHO:Severe and complicated malaria. 2nd ed. Trans R Soc Trop Med Hyg 1990;84(suppl 2):1-65

8) 藤井達也, 木村幹男: 重症マラリアの治療. 化学療法の領域 1998; 14: 803-811

9) 医薬品産業研究所: 寄生虫感染症に対する薬剤. The Medical Letters on Drugs and Therapeutics 1995; 11: 99-108

10) WHO:The use of essential drugs. WHO Tech Rep Ser. No 850.1995;p138

11) 大友弘士: 抗原虫薬. 薬事 1999; 41: 1851-1855

12) 山本康生: 疥癬・ケジラミ. 治療 2000; 82: 920-922

13) Jensen JC, Gugler R:Single-and multiple-dose metronidazole kinetics. Clin Pharmacol Ther 1983;34:481-487

14) 大友弘士: 輸入感染症に対する薬剤の入手法. 知っておきたい現代感染症事情2(中山宏明, ほか編). 1999; pp156-161, 医歯薬出版, 東京

P.222 掲載の参考文献

1) 三鴨廣繁, 伊藤邦彦, 玉舎輝彦: 産婦人科領域における真菌症治療の現状と問題点. Progress in Medicine 1993; 13(12): 42-46

2) 三鴨廣繁, 川添香子, 玉舎輝彦: 抗菌薬の選び方と使い方. A. 感染症の現状と抗菌薬の選び方, 産婦人科領域感染症. Modern Physician 1998; 18(5): 493-498

3) Mikamo H, Izumi K, et al:Comparative study of the effectiveness of oral fluconazole and intravaginal clotrimazole in the treatment of vaginal candidiasis. Infect Dis Obstet Gynecol 1995; 3:7-11

4) Mikamo H, Kawazoe K, et al:Comparative study on the effectiveness of antifungal agents in different regimens against vaginal candidiasis. Chemotherapy 1998;44:364-368

5) 三鴨廣繁, 和泉孝治, ほか: 膣真菌症診断に対するカンジダ培地「フジ」の有用性. 産婦人科の世界 1993; 45(9): 45-48

6) Mikamo H, Kawazoe K, et al:Penetration of oral fluconazole into gynecological tissues. Antimicrob Agents Chemother 1999;43:148-151
pubmed

7) Mikamo H, Kawazoe K, et al:Pelvic abscess and fungemia caused by Candida glabrata.J Infect Chemother 1996;2:294-296

8) 佐藤泰昌, 三鴨廣繁, ほか: 子宮頸癌術後半年後に真菌と好気性/嫌気性菌の複数感染による後腹膜膿瘍をきたした1例. 嫌気性菌感染症研究 1998; 28: 170. 173

9) Mikamo H, Kawazoe K, et al:Penetration of fluconazole into gynaecological tissues. Drug Invest 1995;10:48-52

10) Mikamo H, Kawazoe K, et al:Pharmacokinetics of fluconazole in serum and exudate ofthe pelvic retroperitoneal space after radical hysterectomy and pelvic lymphadenectomy.Drug Invest 1995; 10:104-109

11) 中島茂: 作用機序から眺めた抗真菌薬の現状と展望. 日本医真菌学会雑誌 1999; 40: 119-123

12) 山口英世: 抗真菌薬の耐性機構. 日本医真菌学会雑誌 1999; 40: 199-208

13) 二木芳人, 中島正光, 松島敏春: 全身用抗真菌薬の展望-アゾール系抗真菌薬. 日本医真菌学会雑誌 1999; 40: 163-168

14) Grant SM, Clissold SP:Fluconazole:A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in superficial and systemic mycoses.Drugs 1990;19:877-916

15) Odds FC:Genital candidiasis. Clin Exp Dermatol 1989;7:345-354

16) 玉舎輝彦: 産婦人科薬物療法のすべて. 1996; pp341-343, 金芳堂, 京都

17) Cauwenbergh G:Itraconazole:The first orally active antifungal for single-day treatment of vaginal candidosis. Curr Ther Res Clin Exp 1987;41:210-214

18) 渡辺晋一: 外用真菌剤の現状と展望. 日本医真菌学会雑誌 1999; 40: 151-155

19) 豊田佳代子, 濱田陽子, 高杉益充: 抗真菌薬. f) 抗真菌外用剤. 医薬ジャーナル 1997; 33: 1739-1744

20) Rex JH, Bennett JE, et al:A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia, N Engl Med 1994;331:1325-1330

21) van't Wout JW:Fluconazole treatment of candidal infections caused by non-albicans Candida species. Eur J Clin Microbiol Infect Dis 1996;15:238-242

22) 前崎繁文, 河野茂: 抗真菌薬. a) 抗真菌薬の適応と限界. 医薬ジャーナル 1997; 33: 1706-1712

23) 久米光, 望月真弓, 村瀬勢津子: 抗菌性化学療法薬とその周辺. 抗真菌薬. 化学療法の領域 1996; 12(S-1): 173-182

24) 前崎繁文, 河野茂; 今日の化学療法 1995. 抗真菌剤. 化学療法の領域 1995; 11(S-1): 243-248

P.230 掲載の参考文献

1) White R, Eisenen J, et al:Second gene for gonadotropin-releasing hormone in humans. Proc Natl Acad Sci USA 1998;95:305-309

2) Sherwood N, Lovejoy D, Coe I:Origin of mammalian gonadotropin-releasing hormones. Endocr Rev 1993;14:241-254

3) Sealfon S, Weinstein H, Millar R:Molecular mechanisms of ligand interaction with the gonadotropin-releasing hormone receptor. Endocr Rev 1997;18:180-205

4) Stojilkovic SS, Reinhart J, Catt KJ:Gonadotropin-releasing hormone receptors:Structure and signal transduction pathways. Endocr Rev 1994;15:462-499

5) Imai A, Tamaya T:GnRH receptor and apoptotic signaling. Vitam Horm 1999;59:1-33

6) Conn P, Crowley WF:Gonadotropin-releasing hormone and its analogs. Annu Rev Med 1994; 45:391-405

7) Barbieri R:Ambulatory management of uterine leiomyomata. Clin Obstet Gynecol 1999;42:196-205

8) Golan A:GnRH analogues in the treatment of uterine fibroids.Hum Reprod 1996;11(suppl 3):33-41

9) Broekmans F:GnRH agonists and uterine leiomyomas. Hum Reprod 1996;11(suppl 3):3-25

10) Crosignani P, Vercellini P, et al:GnRH agonists before surgery for uterine leiomyomas. J Reprod Med 1996:41:15-21

11) Shaw R:Blood flow changes in the uterus induced by treatment with GnRH analogues. Hum Reprod 1996;11(suppl 3):27-32

12) Broekmans F, Hompes P, et al:Two-step gonadotropin-releasing hormone agonist treatment of uterine leiomyomas:Standard-dose therapy followed by reduced dose therapy. Am J Obstet Gynecol 1996;175:1208-1216

13) Furui T, Imai A, et al:Differential efficacy of gonadotropin-releasing hormone(GnRH) agonist treatment on pedunculated and degenerated myomas:A retrospective study of 630 women.J Obstet Gynaecol 2000 (in press)

14) Moghissi K:Medical treatment of endometriosis. Clin Obstet Gynecol 1999;42:620-632

15) Reddy S, Rock J:Treatment of endometriosis, Clin Obstet Gynecol 1998;41:387-392

16) Kettel L, Hummel W:Modern medical management of endometriosis. Obstet Gynecol Clin North Am 1997;24:361-373

17) Barlow D:Today's treatments:How do you choose?Int J Gynaecol Obstet 1999;64(suppl 1):S15-21

18) Surrey E, the Add-Back Consensus Working Group:Add-back therapy and gonadotropin-releasing hormone agonists in the treatment of patients with endometriosis:Can a consensus be reached? Fertil Steril 1999;71:420-424

19) Lubianca J, Gordon C, Laufer M:“Add-back”therapy for endometriosis in adolescents. J Reprod Med 1998:43:164-172

20) Fedele L. Bianchi S, et al:Buserelin acetate in the treatment of pelvic pain associated with minimal and mild endometriosis:A controlled study. Fertil Steril 1993;59:516-521

21) Klein K:Precocious puberty:Who has it?Who should be treated?J Clin Endocrinol Metab 1999;84:411-414

22) Merke D, Cutler GJ:Evaluation and management of precocious puberty.Arch Dis Child 1996; 75:269-271

23) Oostdijk W, Rikken B, et al:Final height in central precocious puberty after long term treatment with a slow release GnRH agonist. Arch Dis Child 1996;75:292-297

24) Lincoln E, Zuber T:Management of precocious puberty. Hosp Prac 1998;33:173-176

25) Anasti J:Premature ovarian failure:An update. Fertil Steril 1998;70:1-15

26) Kalantaridou S, Davis S, Nelson L:Premature ovarian failure. Endocrinol Metab Clin North Am 1998;27:989-1006

27) Blumenfeld Z, Haim N:Prevention of gonadal damage during cytotoxic therapy. Ann Med 1997; 29:199-206

28) Diedrich K, Felberbaum R:New approaches to ovarian stimulation. Hum Reprod 1998;13 (suppl 3):1-13

29) Kuwahara A, Matsuzaki T, et al:Induction ofsingle ovulation by sequential follicle-stimulating hormone and pulsatile gonadotropin-releasing hormone treatment. Fertil Steril 1995;64:267-272

30) Lanzone A, Fulghesu A, et al:Gonadotropin-releasing hormone agonist versus human chorionic gonadotropin as a trigger of ovulation in polycystic ovarian disease gonadotropin hyperstimulated cycles. Fertil Steril 1994;62:35-41

31) Kulin H:Delayed puberty. J Clin Endocrinol Metab 1996;81:3460-3464

32) Pickersgill A:GnRH agonists and add-back therapy:Is there a perfect combination?Br J Obstet Gynaecol 1998;105:475-485

P.236 掲載の参考文献

1) Fluckiger E, Wagner HR:2-Br-α-ergokryptin:Beeinfussung von Fertilitat und Laktation bei der Ratte. Experientia 1968;24:1130-1131

2) MacLeod RM, Lehmeyer H:Studies on the mechanism of dopamine-mediated inhibition of prolactin secretion. Endocrinology 1974;94:1077-1085

3) Lachowicz JE, Sibley DR:Molecular characteristics of mammarian dopamine receptors. Pharmacol Toxicol 1997;81:105-113

4) 福田淳, 田中俊誠: ドーパミンagonist療法. 新女性医学大系13, 排卵障害(青野敏博, 編). 1999; pp232-247, 中山書店, 東京

5) Schran HF, Suryakant IB, et al:The pharmacokinetics of bromocriptine in man. Ergot Alkaloid in Neuroendocrine and Neuropsychiatric Aspects(Goldstein M, et al, eds).1980;pp125-139, Raven Press, New York

6) Dallabonzana D, Liuzzi A, et al:Chronic treatment of pathological hyperprolactinemia and acromegaly with the new ergot derivative Terguride. J CIin Endocrinol Metab 1986;63:1002-1007

7) Melis GB, Gambacciani M, et al:Dose-related prolactin inhibitory effect ofthe new long-acting dopamine receptor agonist cabergoline in normal cycling, puerperal and hyperprolactinemic women.J Clin Endocrinol Metab 1987;65:541-545

8) 青野敏博: 図説プロラクチン. 1985; pp74-80, 医歯薬出版, 東京

9) 水野正彦, 藤本征一郎, ほか: ZK 31224(terguride) の産褥性乳汁分泌抑制に対する二重盲検試験成績. 基礎と臨床 1993; 27: 2431-2449

10) 倉智敬一, 青野敏博, ほか: Bromocriptine(Parlodel(R)) による乳汁漏出症の治療成績. 産科と婦人科 1981; 48: 241-248

11) 水野正彦, 藤本征一郎, ほか: ZK 31224(terguride) の高プロラクチン血症および乳汁漏出症に対する二重盲検試験成績. 基礎と臨床 1993; 27: 2451-2476

12) 青野敏博: 乳汁漏出症. 新女性医学大系20, 乳房とその疾患(森宏之, 編). 1999; pp197-205, 中山書店, 東京

P.243 掲載の参考文献

1) Matikainen T, DeLeeu R, et al:Circulating bioactive and immunoreactive recombinant human follicle-stimulating hormone(Org 32489) after administration to gonadotropin-deficient subjects. Fertil Steril 1998;69:S3-S9

2) Kousta E, White DM, et al:Successful induction of ovulation and completed pregnancy using recombinant human luteinizing hormone and follicle stimulating hormone in a woman with Kallmann's syndrome. Hum Reprod 1996;11:70-71

3) Frauser BCMJ:Step-down follicle stimulating hormone regimens in polycystic ovary syndrome. Ovulation Induction:Basic Science and Clinical Advances(Filicori M, Flamigni C, eds).1994; pp 153-162, Excerpta Medica, Amsterdam/Tokyo

4) van Weissenbruch MM, Schoemaker HC, et al:Pharmacodynamics of human menopausal gonadotropin(HMG) and follicle stimulating hormone(FSH). The importance of the FSH concentration in initiating follicular growth in polycystic ovary-like disease.Hum Reprod 1993; 8:813-821

5) Nakamura Y, Yoshimura Y, et al:Clinical experience in the induction of ovulation and pregnancy with pulsatile subcutaneous administration of human menopausal gonadotropin:A low incidence of multiple pregnancy. Fertil Steril 1989;51:423-429

6) Lanzone A, Fulghesu AM, et al:Successful treatment of infertile women with oligomenorrhea using a combination of an LHRH agonist and exogenous gonadotropins. Br J Obstet Gynaecol 1985;92:369-373

7) Urbancsek J, Witthaus E:Midluteal buserelin is superior to early follicular phase buserelin in combined gonadotropin-releasing hormone analog and gonadotropin stimulation in in vitro fertilization. Fertil Steril 1996;65:966-971

8) Rizk B, Aboulghar M, et al:The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome.Hum Reprod Update 1997;3 (3):255-266

9) Ludwig M, Jelkmann W, et al:Prediction of severe ovarian hyperstimulation syndrome by free serum vascular endothelial growth factor concentration on the day of human chorionic gonadotrophin administration. Hum Reprod 1999;14(10):2437-24

P.262 掲載の参考文献

1) 玉舎輝彦: 性ステロイドホルモン薬の使用指針. 産婦人科薬物療法のすべて. 1996; pp13-52, 金芳堂, 京都

2) Kopera H:Actions and patencies of estriol in the human. Steroids and Endometrial Cancer (Jasonni VM, Nenci I, eds).1983;pp175-184, Raven Press, New York

3) Goldzieher JW:Pharmacokinetics and metabolism of ethynyl estrogens. Pharmacology of the Contraceptive Steroids(Goldzieher JW, Fotherby K, eds), 1994;pp127-152, Raven Press, New York

4) Friedman CI, Penney LL:Estrogen and progestin therapy. Drug Therapy in Obstetrics and Gynecology(Ray WF, Zuspan FP, eds),2nd ed.1986;pp316-337, Appleton-Century-Crofts, Norwalk

5) 玉舎輝彦: HRTと乳癌について. 更年期障害Q&A. 1996; pp122-123, 医薬ジャーナル社, 大阪

6) Fitzgerald CT:Hormone replacement therapy and malignancy. Br J Obstet Gynaecol 1993; 100:408-410

7) Barbieri RL:Hormone treatment of endometriosis:The estrogen threshold hypothesis. Am J Obstet Gynecol 1992;166:740-745

8) 玉舎輝彦: HRTの理想と問題点. 産婦人科の世界 1997; 49: 249-256

9) MacDonald RR:Clinical pharmacology of progestogens. Scientific Basis of Obstetrics and Gynaecology(MacDonald RR, ed).1971;pp347-383, JA Churchill, London

10) Fotherby K:Pharmacokinetics and metabolism of progestins in humans, Pharmacology of the Contraceptive Steroids(Goldzieher JW, Fotherby K, eds).1994;pp99-126, Raven Press, New York

11) 玉舎輝彦: 子宮体癌治療上の問題点. 産婦人科の実際 1997; 46: 383-3894

12) Back DJ, Orme ML'E:Drug interactions. Pharmacology ofthe Contraceptive Steroids(Goldzie-her JW, Fotherby K, eds).1994;p409, Raven Press, New York

13) 玉舎輝彦: 月経量・月経周期の異常と機能性子宮出血の治療. 産婦人科薬物療法のすべて. 1996; pp73-122, 金芳堂, 京都

P.268 掲載の参考文献

1) Kerin JF, Liu JH, et al:Evidence for a hypothalamic site of action of clomiphene citrate in women.J Clin Endocrinol Metab 1985;61:265-268

2) 青野敏博, 山口正明 : Clomiphene citrateと他剤の併用による排卵の誘発. 産婦人科の実際 1987;36:151-155

3) Asch RH, Greenblatt RB:Update on the safety and efficacy of clomiphene citrate as a therapeutic agent.J Reprod Med 1976;17:175-180

4) Clark JH, Anderson JN, Peck EJ Jr:Estrogen receptor-anti-estrogen complex:atypical binding by uterine nuclei and effects on uterine growth. Steroids 1973;22:707-71

5) Ferrazzi E, Cartei G, et al:Oestrogen-like effect to tamoxifen on vaginal epithelium. Br Med J 1977;1:1351-1352

6) Gal D, Kopel S, et al:Oncogenic potential of tamoxifen on endometria of postmenopausal women with breast cancer preliminary report Gynecol Oncol 1991;42:120-123

7) Van Leeuwen FE, Benraadt J, et al:Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 1994;343:448-452

8) Taguchi M, Kubota T, Aso T:Direct effect of danazol on the DNA synthesis and ultrastructure of human cultured endometiral stromal cells.Gynecol Obstet Invest 1995;39:192-196

9) El-Roeiy A, Dmowski WP, et al:Danazol but not gonadotropin-releasing hormone agonists suppresses autoantibodies in endometriosis. Fertil Steril 1988;50:864-871
pubmed

10) Black LJ, Sato M, et al:Raloxifene(LYB9481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 1994;3:63-69

P.275 掲載の参考文献

1) Escobar-Morreale HF, et al:Is there a need for T4+T3 combination?Abstract#S58-1, 81st Annual Meeting. American Endocrine Society, June 12 to 15,1999, San Diego

2) Surks MI, DeFesi CR:Normal serum free thyroid hormone concentrations in patients treated with phenytoin or carbamazepine. A paradox resolved.JAMA 1996;275(19):1495-1498
pubmed

3) Vanderpump MP, Tunbridge WM, et al:The incidence of thyroid disorders in the community:A twenty-year follow-up of the Whickham Survey.Clin Endocrinol(Oxf) 1995;43(1):55-68

4) Mandel SJ, Larsen PR, et al:Increased need for thyroxine during pregnancy in women with primary hypothyroidism.N Engl J Med 1990;323:91-96

5) Amino N, Tada H, Hidaka Y:Postpartum autoimmune thyroid syndrome:A model of aggravation of autoimmune disease. Thyroid 1999:9(7):705-713

6) Haddow JE, Palomaki GE, et al:Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. N Engl Med 1999;341(8):549-555

7) Bednarek J, Furmaniak J, et al:Steroid 21-hydroxylase is a major autoantigen involved in adult onset autoimmune Addison's disease. FEBS Lett 1992;309(1):51-55

8) Cowchock FS, McCabe JL, Montgomery BB:Pregnancy after corticosteroid administration in premature ovarian failure(polyglandular endocrinopathy syndrome). Am J Obstet Gynecol 1988;158(1):118-119

9) Wieacker P, Alexopoulos A, et al:Schmangerschaft bei Morbus Addison. Dtsch Med Wochenschr 1989;114:1117-1120

P.284 掲載の参考文献

1) Ludlum DB:Alkylating agents and the nitrosoureas. Cancer:A Comprehensive Treatise. vol5 (Becker FF, ed).1977;pp285-307, Plenum Press, New York

2) Kohn KW:Interstrand cross-linking of DNA by 1,3-bis(2-chloroethyl)-1-nitrosourea and other 1-(2-haloethyl)-1-nitrosoureas.Cancer Res 1977;37:1450-1454

3) Crook TR, Souhami RL, et al:Glutathione depletion as a determinant of sensitivity of human leukemia cells to cyclophosphamide, Cancer Res 1986;46:5035-5038

4) Somfai-Relle S, Suzukake K, et al:Reduction in cellular glutathione by buthionine sulfoximine and sensitization of murine tumor cells resistant to L-phenylalanine mustard. Biochem Pharmacol 1984;33:485-490

5) Mulcahy RT, Dembs NL, Ublacker GA:Enhancement of nitrosourea cytotoxicity by misonidazole in vitro:Correlation with carbamoylating potential. Br J Cancer 1984;49:307-313

6) Henner WD, Peters WP, et al:Pharmacokinetics and immediate effects of high-dose carmustine in man. Cancer Treat Rep 1986;70:877-880

7) de Jong JP, Nikkels PG, et al:Comparative in vitro effects of cyclophosphamide derivatives on murine bone marrow-derived stromal and hemopoietic progenitor cell classes. Cancer Res 1985; 45:4001-4005

8) Lee FY, Workman P:Interaction of nitroimidazole sensitizers with drug metabolizing enzymes Spectral and kinetic studies.Int J Radiat Oncol Biol Phys 1986;12:1383-1387

9) Bergsagel DE, Pruzanski W:Treatment of plasma cell myeloma with cytotoxic agents. Arch Intern Med 1975;135:172-176

10) DeVita VTJ, Hellman S, Rosenberg SA:Cancer Principles and Practice of Oncology, 5th ed.1997, Lippincott, Philadelphia

11) Colvin M:A review of the pharmacology and clinical use of cyclophosphamide. Clinical Pharmacology of Antineoplastic Drugs(Pinedo HM, ed).1978;pp245-261, Elsevier-North Holland. Amsterdam

12) Hilton J:Role of aldehyde dehydrogenase in cyclophosphamide-resistant L1210 leukemia, Cancer Res 1984;44:5156-5160

13) Yeager AM, Kaizer H, et al:Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia using ex vivo marrow treatment with 4-hydroperoxycyclophosphamide. N Engl J Med 1986;315:141-147

14) Brock N, Pohl J, Stekar J:Detoxification of urotoxic oxazaphosphorines by sulfhydryl compounds.J Cancer Res Clin Oncol 1981;100:311-320

15) Cox PJ:Cyclophosphamide cystitis:Identification of acrolein as the causative agent. Biochem Pharmacol 1979;28:2045-2049

16) Green TP, Mirken BL:Prevention of cyclophosphamide-induced antidiuresis by furosemide infusion. Clin Pharmacol Ther 1981;29:634-642

17) Connors TA:Alkylating drugs, nitrosourea and dialkyl triazenes. Cancer Chemotherapy(Pinedo HM, ed).1979;pp22-55, Elsevier-North Holland, Amsterdam

18) Hengst JCD, Kempf RA:Immunomodulation by cyclophosphamide. Clin Immunol, Allergy 1984;4:199-216

19) Alvarado CS, Boat TF, Newman AJ:Late-onset pulmonary fibrosis and chest deformity in two children treated with cyclophosphamide, J Pediatr 1978;92:443-446

20) Andriole GL, Sandlund JT, et al:The efficacy of MESNA(2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy.J Clin Oncol 1987;5:799-803

21) Goren MP, Wright RK, et al:Dechloroethylation of ifosfamide and neurotoxicity. Lancet 1986;i:1219-1220

22) Sutton GP, Blessing JA, et al:Phase II trial of ifosfamide and mesna in patients with advanced or recurrent squamous carcinoma of the cervix who had never received chemotherapy:A Gynecologic Oncology Group study. Am J Obstet Gynecol 1993;168(3 Pt 1):805-807

23) 平林光司, 岡田悦子, ほか: 進行, 再発子宮頸癌に対する254-S, Ifosfamide, Peplomycin併用化学療法の臨床的研究. 日本産科婦人科学会雑誌 1992; 44: 341-348

24) Sutton GP, Blessing JA, et al:Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (a Gynecologic Oncology Group study).Am J Obstet Gynecol 1989;161(2):309-312

25) Sutton GP, Blessing JA, et al:Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus:A Gynecologic Oncology Group study. Am J Obstet Gynecol 1992;166:556-559

26) Heal JM, Franza BR, Schein PS:Pharmacology of nitrosourea antitumor agents. Clinical Pharmacology of Antineoplastic Drugs(Pinedo HM, ed).1978;pp263-275, Elsevier-North Holland, Amsterdam

27) Kann HE Jr:Comparison of biochemical and biological effects of four nitrosoureas with differing carbamoylating activities. Cancer Res 1978;38:2363-2366

28) Tew KD, Sudhakar S, et al:Binding of chlorozotocin and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea to chromatin and nucleosomal fractions of HeLa cells. Cancer Res 1978;38:3371-3378

29) Cascinelli N, Bufalino R, et al:Results of adjuvant interferon study in WHO melanoma programme.Lancet 1994;343:913-914

30) Deppe G, Smith PE:Principles of cancer therapy. Principles of Medical Therapy in Pregnancy.(Gleicher N, ed).1985;pp1401-1449, Plenum Medical Book, New York

31) Bodestein D, Goldin A:A comparison of the effects of various nitrogen mustard compounds onmbryonic cells.J Exp Zool 1948;108:75-91

32) Murphy ML, Bel Moro A, Lacon C:The comparative effects of five poly-functional alkylating agents on the rat fetus, with additional notes. Ann NY Acad Sci 1958;68:762-782

33) Nicholson HO:Cytotoxic drugs in pregnancy.J Obstet Gynaecol Br Commonw 1968;75:307-312

34) Gilliland J, Weinstein L:The effects of cancer chemotherapeutic agents on the developing fetus.Obstet Gynecol Surv 1983;38:6-13

35) Boros SJ, Reynolds JW:Intrauterine growth retardation following third-trimester exposure to busulfan.Am J Obstet Gynecol 1977:129:111-112

36) Lergier JE, Jimenez, et al:Normal pregnancy in multiple myeloma treated with cyclophosphamide.Cancer 1974;34:1018-1022

37) Ortega J:Multiple agent chemotherapy including bleomycin of non-Hodgkin's lymphoma during pregnancy. Cancer 1977;40:2829-2835

38) Spits S:The histological effects of nitrogen mustards on human tumors and tissues. Cancer 1948;1:383-398

39) Miller DG:Alkylating agents and human spermatogenesis. JAMA 1971:217:1662-1665

40) Blake DA, Heller RH, et al:Return of fertility in a patient with cyclophosphamide-induced zoospermia.Johns Hopkins Med J 1976;139:20-22

41) Hinkes E, Plotkin D:Reversible drug-induced sterility in a patient with acute leukemia. JAMA 1973;223(1) 1490-1491

42) Galton DAG, Till M, Wiltshaw E:Busulfan(1,4-dimethyl-sulfbnoxy-butane, Myleran):Summary of clinical results.Ann NY Acad Sci 1958;68:967-973

43) Miller JJ 3rd, Williams GF, Leissring JC:Multiple late complications of therapy with cyclophosphamide,including ovarian destruction.Am J Med 1971;50:530-535

44) Rose DP, Davis TE:Ovarian function in patients receiving adjuvant chemotherapy for breast cancer. Lancet 1977;i:1174-1176

45) Koyama H, Wada T, et al:Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer 1977;39:1403-1409

46) Sutton R, Buzdar AU, Hortobagyi GN:Pregnancy and offspring after adjuvant chemotherapy in breast cancer patients. Cancer 1990;65:847-850

P.295 掲載の参考文献

1) 滝沢憲, 横尾郁子, ほか: 抗癌剤の腹腔内投与によるマウス卵巣卵細胞破壊, 毒性の定量的研究. 日本産科婦人科学会雑誌 1989; 41: 715-722

2) Tanaka T, Hayashi H, et al:Treatment of interstitial ectopic pregnancy with methotrexate:Report of a successful case. Fertil Steril 1982;37:851-852

3) 牧野恒久, 鈴木隆弘, ほか: 子宮外妊娠に対するMTX治療について-卵管妊娠223例の検討. 産婦人科の実際 1998; 47: 927-932

4) 石丸忠之: 子宮外妊娠の保存療法. 産婦人科治療 1997; 75: 447-452

5) 三澤俊哉, 東出香二, 浅井光興: メソトレキセート局所投与が有効であった初産婦における頸管妊娠の1例. 日本産科婦人科学会雑誌 1999; 51: 229-232

6) Matsui H, Eguchi O, Inaba N:A study of first and second line chemotherapies in gestational choriocarcinoma. 日本産科婦人科学会雑誌 1993;45:1297-1304

7) Milunsky A, Graef JW, Gaynor MF:Methotrexate-induced congenital malformation. J Pediatr 1968;72:790-795

8) Warkany J:Aminopterin and methotrexate:Folic acid deficiency. Teratology 1978;17:353-357

9) Sweet DL, Kinzie J:Consequences of radiotherapy and antineoplastic:Therapy for fetus.J Reprod Med 1976;17:241-246

10) Schleunimg M, Clemm CX:Chromosome aberrations in a newborn whose mother received cytotoxic treatment during pregnancy.N Engl Med 1987;317:1666-1667

11) Jones DG, Rutherford LD, et al:Secretion of methotrexate into human milk. Am J Obstet Gynecol 1972;112:978-980

12) Charache S, Condit PT, Humphreys SR:Studies on the foic acid vitamins. IV. The persistence of amethopterin in mammalian tissues. Cancer J 1960;13:236-240

13) Shi Y, Xie X, Zhao C:Effects of ACM sequential chemotherapy on ovarian function in trophoblastic tumors. Chung Hua I Hsueh Tsa Chih 1996;76:45-48
pubmed

14) Rustin GJS, Booth M, et al:Pregnancy after cytotoxic chemotherapy tor gestational trophoblastic tumors. Br J Med 1984;288:103-106

15) 関場香, 矢嶋聰, ほか: 子宮頸癌に対する5-FU錠のPhase II study. 癌と化学療法 1987; 14: 2365-2373

16) Scanlon KJ, Newman EM. et al:Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl A cad Sci USA 1986;83:8923-892

17) 中野修治: 5-フルオロウラシルによるシスプラチンの抗腫瘍効果増強と耐性克服. 医学のあゆみ 1998; 184: 309-313

18) 小西郁生, 南部香成子, ほか: 子宮頸癌に対するNeoadjuvant動注化学療法の直接効果と患者予後. 産科と婦人科 1995; 62: 1237-1241

19) 清水敬生, 荷見勝彦: 子宮頸癌に対するNeoadjuvant chemotherapy-進行子宮頸部腺癌に対するNeoadjuvant chemotherapyの有効性. 産科と婦人科 1993; 60: 1315-1324

20) Macia M, Novo A, et al:Neoadjuvant and salvage chemotherapy with cisplatin(CDDP) and 5-fluorouracil(5-FU) in cervical carcinoma. Eur J Gynaecol Oncol 1993;14:192-196

21) Landoni F, Maneo A, Mangioni C:Concurrent preoperative chemotherapy with 5-fluorouracil and mitomycin C and radiotherapy(FUMIR) followed by limited surgery in locally advanced and recurrent vulvar carcinoma.Gynecol Oncol 1996;61:321-327

22) Stephens JD, Golbus MS, et al:Multiple congenital anomalies in a fetus exposed to 5-fluorouracil during the first trimester. Am J Obstet Gynecol 1980;137:747-749

23) Berry DL, Theriault RL, et al:Management of breast cancer during pregnancy using standardized protocol.J Clin Oncol 1999;17:855-861

24) Song H, Wu P, et al:Pregnancy outcomes after successful chemotherapy for choriocarcinoma and invasive mole:Long term follow-up. Am J Obstet Gynecol 1988;158:538-545

25) 鈴木光明, 関口勲, ほか: UFT投与下での子宮頸癌組織中5-FU濃度. 癌と化学療法 1985; 12: 2139-2144

26) 竹川佳宏, 柏原賢一, ほか: 子宮頸癌におけるUFTの臨床治験. Karkinos 199215: 951-957

27) 竹島信宏, 平井康夫, ほか: UFTによる子宮頸癌に対する補助化学療法の効果. J Jpn Soc Cancer Ther 1996; 31: 297-304

28) Recio FO, Piver MS, et al:Five-year survival after second-line cisplatin-based intraperitoneal chemotherapy for advanced ovarian cancer.Gynecol Oncol 1998;68:267-273

29) Pawliger DF, McLean FW, Noyes WD:Normal fetus after cytosine arabinoside therapy. Ann Intern Med 1971;74:1012
pubmed

30) Baehner RL:Congenital abnormalities in baby born to cytarabine treated mother. Lancet 1980; ii:98-99

P.305 掲載の参考文献

1) Bonadonna G, Delene M, Beretta G:Preliminary clinical screening with adriamycin in lung cancer. Eur J Cancer 1971;7:365

2) Omura G, Blessing JA, et al:Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma:A Gynecologic Oncology Group Study. Cancer 1986;57:1725-1730
pubmed

3) 大熊攻, 太田和雄: Adriamycin心毒性に関する臨床的研究-全国実態調査の集計成績. 癌と化学療法 1981; 8: 596
Medical*Online

4) von Hoff DD, Layard MW, et al:Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979;91:710
pubmed

5) Kunimoto S, Miura K, et al:Cellular uptake and efflux and cytostatic activity of 4'-O-tetrahy-dropyranyladriamycin in adriamycin-sensitive and resistent tumor cell lines.J Antibiot(Tokyo) 1984;37:1697-1702

6) 大熊攻, 吉田一朗, 太田和雄: Anthracycline系抗癌剤の急性心毒性に関する臨床的研究-ホルター心電図による解析. 癌と化学療法 1984; 11: 902-911

7) 刀根弘, 平野伸一, ほか: 新規抗腫瘍性抗生物質(2"R)-4'-ο-Tetrahydropyraniladriamycinのハムスター心機能に対する作用. Jpn J Antibiotics 1986; 39: 547-568

8) 鈴木　忠, 山本裕久, ほか: 4'-epirubicinによる心毒性の検討-doxorubicinとの比較. 癌と化学療法　1984; 11: 2170-2176

9) Ganzina F, Di Pietro N, Magni O:Clinical toxicity of 4'-Epi-Doxorubicin. Tumori 1985;71:233-240

10) Newlands ES, Bagshawe KD, et al:Developments in chemotherapy for medium and high risk patients with gestational trophoblastic tumors. Br J Obstet Gynaecol 1986;93:63-69

11) Vogt SE, Moukhtar M, et al:Chemotherapy for advanced cervical cancer with bleomycin, vincristine, mitomycin C and cis-diamminedichloroplatinum(II).Cancer Treat Rep 1980;64:1005-1007

12) Murad AM, Triginelli SA, et al:Phase II trial of bleomycin, ifosfamide, and carboplatin in metastatic cervical cancer.J Clin Oncol 1994;12:55-59

13) 宮本忠昭: ブレオマイシンによる肺線維症の予防と治療法. 産婦人科の実際 1986; 35: 1747-1752

14) 安部史紀, 吉岡修, ほか: 硫酸ペプロマイシンの生体内分布および吸収排泄に関する研究. Jpn J Antibiotics 1978; 31: 886-894

15) Sugimori H, Iwasaka T, et al:Treatment of advanced cervical cancer by combination of peplomycin, vincristine, mitomycin C and cisplatin. Gynecol Oncol 1989;34:180
pubmed

16) 厚生省薬務局安全課: 医薬品作用情報 No91. 1988

P.310 掲載の参考文献

1) 小畑直子, 河井通泰, ほか: 卵黄嚢腫瘍46例の治療法と予後. 日本婦人科悪性腫瘍化学療法学会誌 1997; 13: 129-133

2) 竹内正七, 土橋一慶, ほか: 子宮頸癌および卵巣癌に対するCPT-11の後期第II相臨床試験. 癌と化学療法 1991; 18: 1681-1689

P.315 掲載の参考文献

1) Rowinsky EK, Cazenave LA, Donehower RC:Taxol:A novel investigational antimicrotubule agent. J Natl Cancer Inst 1990;82:1247-1259

2) Gelmon K:The Taxoids:Paclitaxel and docetaxel. Lancet 1994;344:1267-1272

3) Rowinsky EK, Donehower RC:Paclitaxel(Taxol). N Engl J Med 1995;332:1004-1014

4) 野田起一郎, 池田正典, ほか: Paclitaxel(BMS-181339)の卵巣癌患者に対する臨床第II相試験(3時間点滴静注). 癌と化学療法 1996; 23: 317-325

5) McGuire WP, Hoskins WJ, et al:Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.N Engl J Med 1996;334:1-6

6) NIH Consensus Development Panel on Ovarian Cancer:Ovarian cancer. Screening, treatment, and follow-up.JAMA 1994;273:491-497

7) 製品情報概要タキソール注. 1997, ブリストル・マイヤーズスクイブ株式会社

8) Markman M, Kennedy A, et al:An effective and more convenient drug regimen for prophylaxis against paclitaxel-associated hypersensitivity reactions.J Cancer Res Clin Oncol 1999;125:427-429

P.320 掲載の参考文献

1) Wall ME, Wani MC, et al:Plant antitumor agents.I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata.J Am Chem Soc 1966;88:3888-3890

2) Hsiang YH, Hertzberg R, et al:Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I, J Biol Chem 1985;260:14873-14878

3) 竹内正七, 土橋一慶, ほか: 子宮頸癌および卵巣癌に対するCPT-11の後期第II相臨床試験. 癌と化学療法 1991; 18(10): 1681-1689

4) 板橋正文, 井上務, ほか: CPT-11の生殖・発生毒性試験(第2報)-ラットにおける胎仔器官形成期投与試験. 基礎と臨床 1990; 24(14): 7275-7304

5) 板橋正文, 吉田賢, ほか: CPT-11の生殖・発生毒性試験(第4報)ウサギにおける胎仔器官形成期静脈内投与試験. 基礎と臨床 1990; 24(14): 7324-7336

6) 杉山徹, 西田敬, ほか: 卵巣癌における塩酸イリノテカン(CPT-11) とシスプラチン(CDDP)の併用療法の検討. 日本産科婦人科学会雑誌 1996; 48(9): 927-934

7) 杉山徹: 新しい薬剤を含むレジメの使用経験-効果・副作用-: トポテシン. 婦人科がん化学療法共同研究会化療ニュース 1999; 7(4): 4-6

8) 清水敬生, 梅澤聡, ほか: CDDP耐性卵巣癌に対するCPT-11 + mitomycin-C療法の効果と副作用. 日本癌治療学会誌 1998; 33(3): 77

9) Ovarian Cancer Meta-Analysis Project:Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin and cisplatin chemotherapy of ovarian carcinoma:A meta-analysis.J Clin Oncol 1991;9:1668-1674

P.327 掲載の参考文献

1) Novak E, Yui E:Relation of endometrial hyperplasia to adenocarcinoma of the uterus. Am J Obstet Gynecol 1936;32:674-698

2) Kelly RM, Baker WH:Progestational agents in the treatment of carcinoma of the endometrium. N Engl J Med 1961;2:216-222

3) 杉村基, 寺尾俊彦: 抗ステロイドホルモン剤の臨床適用, 子宮癌. 日本臨牀 1994; 52(3): 804-808

4) 蔵本博行, 上坊敏子, ほか: 子宮体癌に対するホルモン療法. 癌と化学療法 1996; 23(6): 673-677

5) 蔵本博行, 秦宏樹, ほか: 子宮体癌ホルモン療法の作用機序. 癌と化学療法 1989; 16(4): 1851-1857

6) 栗原操寿, 岡田弘二, ほか: 子宮内膜癌に対するMedroxyprogesterone acetate(MPA)の治療効果に関する検討. 産婦人科の実際 1985; 34(4): 517-536

7) 佐藤信二, 矢嶋聰, ほか: 子宮体癌に対する補助化学療法としてのMPAの有効性に関する研究. 子宮体がん化学療法第二次研究. Oncology & Chemotherapy 1996; 12(2): 172-181

8) 医療薬日本医薬品集, 1998-1999, 第22版(日本医療情報センター編). 1998, じほう(薬業時報社), 東京

9) 蔵本博行, 上坊敏子, ほか: 子宮内膜癌に対する妊孕性温存療法の可能性. 産婦人科治療 1995; 71(2): 117-120

10) Anzai Y, Holinka CF, et al:Stimulatory effects of 4-hydroxytamoxifen on proliferation of human endometrial adenocarcinoma cells(Ishikawa line). Cancer Res 1989;49:2362-2365

11) Sedati A, Mariani L, et al:The effectiveness of danazol therapy in postmenopausal women effected by endometrial hyperplasia. Clin Exp Obstet Gynecol 1992;19(3):161-165

12) 曾栄輝, 沼口正英, ほか: 子宮内膜症に対するDanazol, Tamoxifenの治療成績. 癌と化学療法 1989; 16(4): 1612-1622

13) Kauppila A, Isatalo H, et al:Short-term effects of danazol and medroxyprogesterone acetate on cytosol and nuclear estrogen and progestin receptors,17β-hydroxysteroid dehydrogenase activity, histopathology, and ultrastructure of human endometrial adenocarcinoma.Int J Cancer 1985; 35:157-163

14) Srkalovic G, Wittliff JL, et al:Detection and partial characterization of receptors for[D-Trip6]-luteinizing hormone-releasing hormone and epidermal growth factor in human endometrial carcinoma. Cancer Res 1990;50(15):1841-1846

15) Pahwa GS, Kullander S, et al:Specific low affinity binding sites for gonadotropin-releasing hormone in human endometrial carcinomata. Eur J Obstet Gyneol Reprod Biol 1991;41:135-142

16) Gallagher CJ, Oliver RTD, et al:A new treatment for endometrial cancer with gonadotrophin releasing-hormone analogue. Br J Obstet Gynaecol 1991;98:1037-1041

17) Bruckner HW, Montwani BT:Treatment of advanced refractory ovarian carcinoma with a gonadotropin-releasing hormone analogue. Am J Obstet Gynecol 1989;161(5):1216-1218

18) Miller DS, Brady MF, Barrett RJ:A phase II trial of leuprolide acetate in patients with advanced epithelial ovarian carcinoma. Am J Clin Oncol 1992;15(2):125-128

19) Lind MJ, Cantwell BMJ, et al:A phase II trial of goserelin(Zoladex) in relapsed epithelial ovarian cancer, Br J Cancer 1992;65:6214-623

P.332 掲載の参考文献

1) Fujimoto J, Ichigo S, et al:Progestins and danazol effect on cell to cell adhesion, and E-cadherin and α-and β-catenin mRNA expressions.J Steroid Biochem Mol Biol 1996;57:275-282

2) Fujimoto J, Hori M,et al:Sex steroids regulate the expression of plasminogen activator inhibitor-1(PAI-1) and its mRNA in endometrial cancer cell line Ishikawa.J Steroid Biochem Biol 1996;59:1-8

3) Fujimoto J, Hosoda S, et al:Inhibition of tumor angiogenesis activity by medroxyprogesterone acetate in gynecologic malignant tumors. Invasion Metastasis 1989;9:269-277

4) Nemunaitis J, Poole C, et al:Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor Marimastat on serum tumor markers in advanced cancer:Selection of a biologically active and tolerable dose for long-term studies. Clin Cancer Res 1998;4:1101-1110

5) Fujimoto J, Hori M, et al:Plausible novel therapeutic strategy of uterine endometrial cancer with reduction of basic fibroblast growth factor secretion by progestin and O-(chloroacetyl-car-bamoyl) fumagillol[TNP-470;AGM-1470], Cancer Lett 1997;113:187-194

6) Griffith EC, Su Z, et al:Methionine aminopeptidase(type 2) is the common target for angiogenesis inhibitor AGM-1470 and ovalicin. Chem Biol 1997;4:461-471

7) Gagliarde A, Hadd H, Collins DC:Inhibition of angiogenesis by suramin. Cancer Res 1992; 52:5073-5075

8) Pesenti E. Sola F, et al:Suramin prevents neovascularization and tumor growth through blocking of basic fibroblast growth factor activity. Br J Cancer 1992;66:367-372

9) D'Amato R, Loughnan MS, et al:Thalidomide is a inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91:4082-4085

10) Wamil BD, Thurman GB, et al:Soluble E-selectin in cancer patients as a marker ofthe therapeutic efficacy of CM 101, a tumor inhibiting agent, evaluated in phase I clinical trial. J Cancer Res Clin Oncol 1997;123:173-179

11) Gradishar WJ:An overview of clinical trials involving inhibitors of angiogenesis and their mechanism of action.Invest New Drugs 1997;15:49-59

12) Sato Y, Abe M, Takaki R:Platelet factor 4 blocks the binding of basic fibroblast growth factor to the receptor and inhibits the spotaneous migration of vascular endothelial cells. Biochem Biophys Res Commun 1990;172:595-600

13) Gengrinovitch S, Greenberg SM, et al:Platelet factor-4 inhibits the mitogenic activity of VEGF121 and VEGF165 using several concurrent mechanism. J Biol Chem 1995;270:15059-15065

14) O'Reilly MS, Holmgren L, et al:Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996;2:689-692

15) Kogn EC, Liotta LA:Molecular insights into cancer invasion:Strategies for prevention and intervention.Cancer Res 1995;55:1856-1862

P.338 掲載の参考文献

1) Cunningham FG, MacDonald PC(eds):Williams Obstetrics,19th ed.1993;p269, Appleton and Lange, Stamford

2) 勝田信夫: 現代の薬理学(田中潔, 編著). 1968; p257, 金原出版, 東京

3) Cunningham FG, MacDonald PC (eds) : Williams Obstetrics. 19th ed. 1993 ; pp485-487, Appleton and Lange, Stamford

4) 鮫島浩, 池ノ上克: 子宮収縮と胎児仮死. 周産期医学 1995; 25(8): 1061-1064

5) 松本公一郎, 津田健, ほか: 16,16-Dimethyl-trans-Δ2-prostaglandin E1 methylester(ONO-802)のラット及びウサギの卵巣機能に及ぼす影響. 日本薬理学雑誌 1982; 79: 15-22

6) 松本公一郎, 柴田邦治, ほか: 妊娠中期のラットの羊膜外に投与したProstaglandin F2αの妊娠におよぼす影響および繁殖試験. 応用薬理 1975; 10: 753-760

P.342 掲載の参考文献

1) Fuchs A-R, Fuchs F:Ethanol for prevention of preterm birth. Semin Perinatol 1981;5:236-251

2) Norwitz ER, Robinson JN, Challis JRG:The control of labor. N Engl Med 1999;341:660-666

3) Cox SM, Sherman ML, Leveno KJ:Randomized investigation of magnesium sulfate for prevention of preterm birth.Am JObstet Gynecol 1990;163:767-772

4) 西島正博, 谷昭博: 子宮収縮抑制剤のリスク, ベネフィット. 日本産科婦人科学会雑誌 1998; 50: N55-N58

5) Leveno KJ, Klein VR, et al.:Single-centre randomized trial of ritodrine hydrochloride for preterm labour. Lancet 1986;1:1293-1296

6) Canadian Preterm Labor Investigators Group:Treatment of preterm labor with the beta-adrenergic agonist ritodrine.N Engl J Med 1992;327:308-312

7) Panter K, Tan B, Hannah M:Indomethacin vs β-mimetics for the tocolysis of preterm labor:A meta-analysis of RCTs. Am J Obstet Gynecol 1996;174:466(abstract)

8) Saade GR, Taskin O, et al.:In vitro comparison of four tocolytic agents alone and in combination. Obstet Gynecol 1994;84:374-378

9) Papatsonis DNM, Van Geijn HP, et al.:Nifedipine and ritodrine in the management of preterm labor:A randomized multicenter trial.Obstet Gynecol 1997;90:230-234

10) Glock JL, Morales WJ:Efficacy and safety of nifedipine versus magnesium sulfate in the treatment of preterm labor:Randomized study.Am J Obstet Gynecol 1993;169:960-964

11) Andersen LF, Lyndrup J, et al.:Oxytocin receptor blockade:A new principle in the treatment of preterm labor?Am J Perinatol 1989;6:196-199

12) Goodwin TM, Valenzuela G, et al.:Treatment of preterm labor with the oxytocin antagonist atosiban.Am J Perinatol 1996;13:143-146

13) Goodwin TM, Zograbyan A:Oxytocin receptor antagonists:Update. Clin Perinatol 1998;25:859-871

14) Clavin DK, Bayhi DA, et al:Comparison of intravenous magnesium sulfate and nitroglycerin for preterm labor:Preliminary data. Am J Obstet Gynecol 1996;174:307(abstract)

P.348 掲載の参考文献

1) Cunningham FG, MacDonald PC, et al:The puerperium. Williams Obstetrics,20th ed.1997; pp535-540, Appleton & Lange, Connecticut

2) Rebar RW:The breast and the physiology of lactation. Maternal-Fetal Medicine(Creasy RK, Resnik R, eds),4th ed.1999;pp106-121, WB Saunders, Philadelphia

3) 武谷雄二: Overview-乳汁分泌の内分泌的調節機序. 臨床婦人科産科 1996; 50: 876-880

4) Kleinberg DL:Role of IGF-I in normal mammary development. Breast Cancer Res Treat 1998;47:201-208

5) 青野敏博, 横山裕司: 乳汁分泌のメカニズム. ペリネイタルケア 1992; 11: 155-159

6) 青野敏博, 苛原稔, 東敬次郎: 乳汁分泌のホルモンによる調節. 臨床婦人科産科 1990; 44: 541-549

7) 山中美智子, 多賀理吉: 母乳分泌のメカニズム. 周産期医学 1996; 26: 477-480

8) Aono T, Shioji T, et al:Effect of sulpiride on poor puerperal lactation. Am J Obstet Gynecol 1982;143:927-932

9) 本庄英雄: 乳汁分泌抑制. 産婦人科の薬物療法(岡田弘二, 編). 1995; pp154-159, 医薬ジャーナル社, 大阪

10) 水野正彦, 藤本征一郎, ほか: ZK31224(Terguride)の産褥性乳汁分泌抑制に対する二重盲検試験成績. 基礎と臨床 1993; 27: 2431-2449

11) 青野敏博, 田村紀子: 乳汁分泌の薬剤によるコントロール. 臨床婦人科産科 1996; 50: 888-890

P.352 掲載の参考文献

1) Briggs GG, Freeman RK, Yaffe SJ:Drugs in Pregnancy and Lactation,4th ed.1994, Williams & Wilkins, Baltimore

2) Bauman WA, Yalow RS:Transplacental passage of insulin complexed to antibody. Proc Natl Acad Sci USA 1981;78:4588-4590

3) Coetzee EJ, Jackson WPU:The management of non-insulin-dependent diabetes during pregnancy.Diabetes Res Clin Pract 1985-1986;1:281-287

4) Coetzee EJ, Jackson WPU:Oral hypoglycaemics in the first trimester and fetal outcome.S Afr Med J 1984;65:635-637

5) Piacquadio K, Hollingsworth DR, Murphy H:Effects of in-utero exposure to oral hypoglycaemic drugs.Lancet 1991;338:866-869

6) Hellmuth E, Damm P, Molsted-Pedersen L:Congenital malformations in offspring of diabetic women treated with oral hypoglycaemic agents during embryogenesis.Diabet Med 1994;11:471-474

7) Elliott BD, Schenker S, et al:Comparative placental transport of oral hypoglycemic agents in humans:A model of human placental drug transfer. Am J Obstet Gynecol 1994;171:653-660

8) Sivan E, Feldman B, et al:Glybride crosses the placenta in vivo in pregnant rats. Diabetologia 1995;38:753-756

9) Jovanovic L, Peterson CM:Insulin and glucose requirements during the first stage of labor in insulin-dependent diabetic women. Am J Med 1983;75:607-612

10) Jovanovic L, Ilic S, et al:Metabolic and immunologic effects of insulin lispro in getational diabetes.Diabete Care 1999;22:1422-1427

P.363 掲載の参考文献

1) Naden RP, Redman CWG:Antihypertensive drugs in pregnancy. Clin Perinatol 1985;12:521-583

2) Sibai BM, Mercer BM, et al:Aggressive versus expectant management ofsevere preeclampsia at 28 to 32 week's gestation:A randomized controlled trial. Am J Obstet Gynecol 1994;171:818-82

3) 周藤雄二, 中本収, ほか: 当科における重症妊娠中毒症の管理とその臨床的背景. 日本妊娠中毒症学会雑誌, 1995; 3: 115-116

4) 日高敦夫, 友田昭二, ほか: 妊娠中毒症のターミネーション. 産婦人科の実際 1989; 38: 987-997

5) Davey DA:Hypertensive disorders of pregnancy. Dewhurst's Textbook of Obstetrics & Gynecology for Postgraduates,5th ed(Charles R, Whitfield P, eds).1995;pp175-215, Blackwell Science

6) Lindheimer MD, Akbari A : Hypertension in pregnancy. 産婦人科の進歩 1997;6:635-647

7) 日高敦夫: 妊娠中毒症-その病態論的アプローチ-母児循環動態に関する基礎的臨床的研究. 日本産科婦人科学会雑誌 1988; 40: 1010-1020

8) 中本収, 周藤雄二, 日高敦夫: 妊娠中毒症の母体管理-薬物療法. 周産期医学 1995; 25: 1611-1618

9) 日高敦夫, 島津隆, ほか: 妊娠中毒症と薬物療法の問題点. 産婦人科の世界 1980; 32: 1307-1311

10) 中本収, 周藤雄二, ほか: 症例からみた妊娠中毒症重症高血圧治療薬としての硫酸マグネシウムの有効性について. 産科と婦人科 1998; 65: 646-657

11) 日高敦夫, 友田昭二, ほか: 妊娠高血圧症の管理. 第1回腎と妊娠研究会. 1992; pp52-61, 東京医学社, 東京

12) Kitanaka T, Hidaka A, et al:Amargin of safety of fetus in patients with severe pregnancy induced hypertension. Hypertension in Pregnancy(Cosmi EV, Renzo GC, eds).1991;pp557-561, Monduzzi Editore, S.p.A-Bologna(ltaly)

13) 中本収, 日高敦夫, ほか: 妊娠中毒症HP型の高血圧重症度からみたターミネーション. 日本妊娠中毒症学会雑誌 1998; 6: 63-68

P.369 掲載の参考文献

1) 吉田幸洋, 桑原慶紀: 妊婦の自己抗体と周産期管理. 産科と婦人科 1994; 61: 1013-1019

2) Buyon JP:Autoantibodies reactive with Ro(SSA) and La(SSB) and pregnancy.J Rheumatol 1997;24:12-16

3) Kaaja R, Julkunen H, et al:Intravenous immunoglobulin treatment of pregnant patients with recurrent pregnancy losses associated with antiphospholipid antibodies. Acta Obstet Gynecol Scand 1993;72:63-66

4) Nakamura Y, Yoshida K, et al:Immunoadsorption plasmapheresis as a treatment for pregnancy complicated by systemic lupus erythematosus with positive antiphospholipid antibodies. AJRI 1999;41:307-311

P.375 掲載の参考文献

1) Guntheroth WG, Cyr DR, et al:Hydrops from reciprocating atrioventricular tachycardia in a 27-week fetus requiring quinidine for conversion. Obstet Gynecol 1985;66:29S-33S

2) Truccone N, Mariona F:Intrauterine conversion of fetal supraventricular tachycardia with combination of digoxin and verapamil Pediatr Pharmacol (New York) 1985;5:149-153

3) Rey E. Duperron L, et al:Transplacental treatment of tachycardia induced fetal heart failure with verapamil and amiodarone:A case report. Am J Obstet Gynecol 1985;153:311-312

4) Harrison MR, Golbus MS, Filly RA(eds):The Unborn Patients:Prenatal Diagnosis and Treatment,2nd ed.1990;pp990-1012, WB Saunders, Philadelphia

5) 中西敏雄, 中沢誠, 寺井勝: 胎児・未熟児における強心薬の心血管系への影響. 周産期学シンポジウム 1996; 14: 87-98

6) Wiggins JW, Bowes W, et al:Echocardiographic diagnosis and intravenous digoxin management of fetal tachyarrhythmia and congenstive heart failure. Am J Dis Child 1986;140:202-204

7) Maeda H, Shimokawa H, Nakano H:Effects of intrauterine treatment on nonimmunologic hydrops fetalis.Fetal Ther 1988;3:198-209

8) De Lia JR, Emery MG. et al:Twin transfusion syndrome:Successfull in utero treatment with digoxin. Int J Gynaecol Obstet 1985;23:197-201

9) Naides SJ, Weiner CP:Antenatal diagnosis and palliative treatment of non-immune hydrops fetalis secondary to fet al parvovirus B19 infection.Prenat Diagn 1989;9:105-114

10) Sahakian V, Weiner CP, et al:Intrauterine transfusion treatment of nonimmune hydrops fetalis secondary to human parvovirus B19 infection. Am J Obstet Gynecol 1991;164:1090-1091

11) Liggins GC, Howie MB:A controlled trial of antepartum glucocorticoid treatment of prevention of the respiratory distress syndrome in premature infant Pediatrics 1972;50:515-525

12) Collaborative group on antenatal steroid therapy:Effect of antenatal dexamethasone administration.1985, National Institute of Health, Washington DC

13) Wu B, Kikkawa Y, et al:The effect of thyroxine on the maturation of fetal rabbit lungs. Biol Neonate 1973;22:161-168

14) Marchant B, Brownlie BE, et al:The placental transfer of propylthiouracil, methimazole and carbimazole. J Clin Endocrinol Metab 1977;45:1187-1193

15) Davidson KM, Richards DS, et al:Successful in utero treatment of fetal goiter and hypothyroidism. N Engl J Med 1991;324:543-546

16) Noia G, De Santis M, et al:Early prenatal diagnosis and therapy of fetal hypothyroid goiter. Fetal Diagn Ther 1992;7:138-142

17) Evans MI:Pharmacologic suppression of the fetal adrenal gland in utero:Attempted prevention of abnormal external genital masculinization in suspected congenital adrenal hyperplasia.JAMA 1985:253:1015-1020

18) Forest MG, Betuel H, David M:Prenatal treatment in congenital adrenal hyperplasia due to 21-hydroxylase deficiency:Up-date 88 of the French multicentric study. Endocr, Res 1989;15:277-301

19) Daly LE, Kirke PN, et al:Folate levels and neural tube defects:Implications for prevention. JAMA 1995;274:1698-1702

P.383 掲載の参考文献

1) 日本母性保護産婦人科医研修ノートNo62, 母胎救急疾患こんな時どうする. 1999

2) 厚生省心身障害研究, 妊産婦死亡の防止に関する研究. 平成7年度研究報告書. 1996

3) 厚生省児童家庭局母子保健課(監): 母子保健の主なる統計, 平成10年度. 1998

4) 江端俊彰: 各種ショックの特徴と治療目標. 産科と婦人科 1992; 59(増刊号): 3-6

5) 上林茂暢, 宮崎康, ほか: 臨床医の注射と処方, 第7版. 1997, 医歯薬出版, 東京

6) 千村哲朗: 敗血症性ショック. 図説産婦人科VIEW 24, 周産期の救急医療(中林正雄, 武田佳彦, 編). 1996, メジカルビュー社, 東京

7) 水島裕, 宮本昭正(編著): 今日の治療薬. 1999, 南江堂, 東京

8) 堀雄一, 奥田俊洋: 酸・塩基平衡. 内科 1998; 82(4): 622624

9) Adrogue HJ, Madias N E:Management of life-threatening acid-base disorders. N Engl J Med 1998;338:26-34

P.391 掲載の参考文献

1) 朝倉英策, 斉藤正典: DICの病型とその対策. 臨床血液 1995; 36: 314-319

2) 倉地幸徳: 凝固・線溶系・キニン. 1979; pp343-353, 中外医学社, 東京

3) 小出武比古: アンチトロンビンIIIの構造と機能. 血液凝固の抑制調整機構. 1991; pp17-20, 西村書店, 新潟

4) 林辰弥, 鈴木宏治: アンチトロンビンIIIと外因性凝固阻害物質による血液凝固の抑制. 血液・腫瘍科 1993; 26(1): 50-59

5) 岡島研二: 血管内皮細胞障害の薬物による治療. 集中治療 1998; 10(1): 87-93

6) Terao T, Kobayashi T, et al:Pathological state of the coagulatory and fibrinolytic system in preeclampsia and the possibility of its treatment with AT III concentrate.Asia-Oceania J Obstet Gynaecol 1989:15(1):25-32

7) Buller HR, Weenink AH, et al:Severe antithrombin III deficiency in a patient with pre-eclampsia. Observations on the effect of human AT III concentrate transfusion. Scand J Haematol 1980; 25:81-86

8) 真木正博, 寺尾俊彦, ほか: 乾燥濃縮人アンチトロンビンIII製剤の純粋重症妊娠中毒症に対する臨床評価. 診療と新薬 1996; 33(1): 67-94

9) 前川正, ほか: DICにおけるプロトロンビンとアンチトロンビンIIIの回転. 厚生省特定疾患, 汎発性血管内凝固症調査研究班, 昭和55年度業績集報告. 1970; pp33-43

10) 真木正博, 寺尾俊彦, 池ノ上克: 産科婦人科領域のDICに対するBI6.0l3(アンチトロンビンIII濃縮製剤)単独投与の有用性の検討. 産婦人科治療 1986; 52(1): 611-619

11) 辻肇: アンチトロンビンIII. 臨床血液 1990; 31(6): 750-755

12) 真木正博, 寺尾俊彦, ほか: 産科的DICに対するアンチトロンビンIII濃縮製剤の治療効果. 日本産婦人科・新生児血液学会誌 1994; 4(1): 37-49

13) Rosenberg RD:Chemistry of the hemostatic mechanism and its relationship to the action of heparin. Fed Proc 1977;36:10-18

14) 真木正博: 産科的DIC. 産婦人科MOOK 11分娩時出血の管理. 1980; pp198-210, 金原出版, 東京

15) 松田保: DICの治療. 日本医学会総会20回会誌1979; II: 1283-1287

16) Uchiba M, Okajima K et al:Attenuation of endotoxin-induced pulmonary vascular injury by antithrombin III. Am J Physiol 1996;270:L921-L930

17) Warkentin TE, Levine MN, et al:Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin.N Engl J Med 1995;332:1330-1335
pubmed

18) Andersson LO, Barrowcliffe TW, et al:Anticoagulant properties of heparin fractionated by affinity chromatography on matrix bound antithrombin III and by gel filtration. Thromb Res 1976;9:575-583

19) Andersson LO, Barrowcliffe TW, et al:Molecular weight dependency ofthe heparin potentiated inhibition of thrombin and activated Factor X. Effect of heparin neutralization in plasma. Thromb Res 1979;15:531-541

20) 櫻川信男, 長谷川淳, ほか: 汎発性血管内血液凝固症(DIC)に対する抗凝固薬FR-860の臨床効果. 基礎と臨床 1991; 25(13): 4153-4177

21) 櫻川信男, 長谷川淳, ほか: 汎発性血管内血液凝固症(DIC)に対する低分子ヘパリン(FR-860) の臨床評価. 臨床医薬 1992; 8(2): 423-452

22) 藤井浩, 清水忠雄, ほか: 急性DICの治療. 臨床血液 1982; 23: 1696-1705

23) 小西正昭, ほか: メシル酸ガベキサートのin vitroにおける凝固・線溶系に及ぼす影響. 日本血液学会雑誌 1978; 41: 229

24) Ohno H, Kosaki G, et al:FOY:[ethyl p-(6-guanidinohexanoyloxy) benzoate]methanesul-fonate as a serine proteinase inhibitors. I. Inhibition of thrombin and factor Xa in vitro. Thromb Res 1980;19:579-588

25) Kosaki G, Nomura T, Kambayashi J:The mechanism of the inhibitory effect of protease inhibitors on platelet aggregation and cellular synthesis of prostaglandins, Thromb Res 1980;20:587-598

26) 神前五郎, 上林純一, ほか: DICに対するFOYの治療効果に関する研究. 医学のあゆみ 1983; 124(2): 144-154

27) 高橋芳右, 柴田昭: メシル酸ナファモスタット(FUT-175), メシル酸ガベキサート(FOY)およびヘパリンの抗凝固・抗線溶作用の比較検討. 臨床と研究 1988; 65: 3503-3510

28) 稲場均, 加藤克明, ほか: ウリナスタチンの抗DIC作用の検討. 日本薬理学雑誌 1986; 88; 239-244

P.401 掲載の参考文献

1) 寮隆吉: ベッドサイドの新輸血学-効果的な輸血・輸液の実際. 1998, メジカルビュー社, 東京

2) 血液製剤使用の適正化について. 1999, 厚生省薬務局

P.406 掲載の参考文献

1) 水島裕, 宮本昭正(編著): 血液に作用する薬剤25. 造血薬. 今日の治療薬解説と便覧'99. 1999; pp403-411, 南江堂, 東京

2) 澤田賢一: 鉄剤(造血薬)フェロミア. Medicina 1996; 33: 272-273

3) 三輪哲義: 貧血と多血・治療: 主な貧血の治療方針決定と最新の治療の実際, 鉄欠乏性貧血の診療のポイント-鉄動態の理解に基づいた鉄欠乏性貧血の治療方針の決定と最新の治療戦略. Meedical Practice 1998; 15: 1551-1564

4) 大塚輝久, 仁保善之: 貧血と多血・セミナーエリスロポエチン, その他の造血因子による治療の実際-適応と成績. Medical Practice 1998; 15; 1533-1536

P.414 掲載の参考文献

1) 市川陽一, 川合眞一: 膠原病治療薬の薬理と有害反応. ステロイドホルモン. A. 種類と特徴. 臨床薬物治療学大系16, 膠原病/血液疾患(水島裕, ほか編). 1987; pp17-21, 情報開発研究所, 東京

2) 水島裕, 宮本昭正(編著): 今日の治療薬 '99. 1999, 南江堂, 東京

3) 川合眞一, 水島裕: 合成グルココルチコイド療法の副作用とその対策. 日本臨牀 1994; 52: 767-772

4) 川合眞一, 市川陽一: 合成グルココルチコイド剤と他薬剤との相互作用. 日本臨牀 1994; 52: 773-778

5) 川合眞一: 抗炎症薬の臨床薬理. 臨床薬理学(日本臨床薬理学会, 編). 1996; pp391-401, 医学書院, 東京

6) 川合眞一: COX-2阻害薬. 医学のあゆみ 1999; 190: 966-970

7) Kawai S:Cyclooxygenase selectivity and the risk of gastrointestinal complications of various nonsteroidal anti-inflammatory drugs:A clinical consideration. Inflamm Res 1998;47(suppl 2):S102-S106

P.418 掲載の参考文献

1) Weinstein L:Syndrome of hemolysis, elevated liver enzymes, and low platelet count:A severe consequence of hypertension in pregnancy. Am J Obstet Gynecol 1982;142:159-167

2) 玉舎輝彦: 産婦人科薬物療法の基本と応用. 1992; p131, 金芳堂, 京都

3) 添付文書

4) Messinis IE, Lolis DE, et al:Effect of metoclopramide on maternal and fetal prolactin secretion during labor. Obstet Gynecol 1982;60(6):686-688

5) Jewell D, Young G:Treatments for nausea and vomiting in early pregnancy. The Cochrane Library, Issue 4.1998, Update Software, Oxford

6) 佐藤孝道, 加野弘道, ほか: 実践妊娠と薬. 1996; p294, 薬業時報社, 東京

7) 舛田和之, 石井清一, ほか: 脛骨列形成不全症における足部再建術の小経験. 整形外科 1988; 39(1): 109-113

8) Szabo KT, Brent RL:Letter:Species differences in experimental teratogenesis by tranquillising agents, Lancet 1974;i:565
pubmed

P.422 掲載の参考文献

1) 古江尚: 4. 消化器症状とその対策-B. 悪心・嘔吐. がん化学療法の副作用対策(吉田清一, 監修). 1996; pp199-121, 先端医学社, 東京

2) 塚越茂, 太田潤, 田口鐵男: 5-HT3受容体拮抗剤について(1)-薬理作用について. 癌と化学療法 1993; 20: 2108-2114

3) 宮田桂司, 本田一男: セロトニン(5-HT3)受容体拮抗薬と消化器領域における薬理作用. 日本薬理学雑誌 1994; 104: 143-152

4) 水谷勝美: VI. 副作用対策(支持療法). 2)消化器症状(1)HT3ブロッカー. 産科と婦人科 1999; 66: 1645-1651

P.432 掲載の参考文献

1) Gurwits ZJH, Avorn, J, Bohn RL:Initiation of antihypertensive treatment during nonsteroidal anti-illflammatory drugs therapy.JAMA 1994;272:71-76

2) Oler A, Whooley MA, et al:Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. JAMA 1996;276:811-815

3) Hong WK, Sporn MB:Recent advances in chemoprevention ofcancer. Science 1997;278:1073-1077

4) Slone D, Heinonen OP, et al:Aspirin and congenital malformations. Lancet 1976;i:1373-1375

5) Klebanofr MA:Aspirin exposure during the first 20 weeks of gestation and IQ at four years age. Teratology 1987;35:211-219

6) Tulppala M, Marttunen M, et al:Low-dose aspirin in prevention of miscarriage in women with unexplained or autoimmune-related recurrent miscarriage:Effect on prostacyclin and thromboxane A2 production. Hum Reprod 1997;12:1567-1572
pubmed

7) Benigni A, Gregorini G, et al:Effect of low-dose aspirin on fetal and maternal generation of thromboxane by platelcts in women at risk for pregnancy-induced hypertension.N Engl Med 1989;321:357-362

8) Schiff E, Peleg E, et al:The use of aspirin to prevent pregnancy-induced hypertension and lower the rate of thromboxane A2 to prostacyclin in relatively high risk pregnancies.N Engl Med 1989;321:321-326

9) Caritis S:Low-dose aspirin to prevent preeclampsia in women at high risk.N Engl Med 1998;338 1701-705

10) Morales WJ, Smith SG, et al:Eflicacy and safety of indomethacin versus ritodrine in the management of preterm labor:A randomized study. Obstet Gynecol 1989;74:567-572

11) Van Den Veyver IB, Moise KJ Jr, et al:The effect of gestational age and fetal indomethacin levels on the incidence of constriction of the fetal ductus arteriosus. Obstet Gynecol 1993;82:500-503

12) Moise KJ Jr:Effect of advancing gestational age on the frequency of fetal ductal constriction in association with maternal indomethacin use. Am J Obstet Gynecol 1993;168:1350-1353

13) Vermillion ST, Scardo JA, et al:The effect of indomethacin tocolysis on fetal ductus arteriosus constriction with advancing gestational age. Am J Obstet Gynecol 1997;177:256-261

P.444 掲載の参考文献

1) 糸川嘉則: 妊婦のためのビタミン・ミネラル読本. 1990, メディカ出版, 大阪

2) 日本ビタミン学会(編): ビタミンハンドブック1, 脂溶性ビタミン. 1989, 化学同人, 京都

3) 日本ビタミン学会(編): ビタミンハンドブック2, 水溶性ビタミン. 1989, 化学同人, 京都

4) 日本ビタミン学会(編): ビタミンの事典. 1996, 朝倉書店, 東京

P.450 掲載の参考文献

1) Clark AL:Clinical uses of intravenous immunoglobulin in pregnancy. Clin Obstet Gynecol 1999;42:368-380

2) A combined study from centres in England and Baltimore:Prevention of the Rh-haemolytic disease:Results of the clinical trial. Brit Med S 1966;2:907-914

3) Coulam CB, Krysa L, et al:Intravenous immunoglobulin for treatment of recurrent pregnancy loss. Am J Reprod Immunol 1995;34:333-337

4) Miyasaki K, Mizutani H, et al:Activated(HLA-DR+) T-lymphocyte subsets in cervical carcinoma and effects of radiotherapy and immunotherapy with sizofiran on cell-mediated immunity and survival. Gynecol Oncol 1995;56:412-420

5) Toma H, Tanaka K, et al:Pregnancy in women receiving renal dialysis and transplantation in Japan:A nationwide study. Nephrol Dial Transplant 1999;14:1511-1516

6) Kalantandou SN, Braddock DT, et al:Treatment of autoimmune premature ovarian failure. Hum Reprod 1999;14:1777-1782

7) Coulam CB:Immunotherapy for recurrent spontaneous abortion. Early Pregnancy. Biology and Medicine 1995;1:13-26

8) Cowley PA:Antenatal corticosteroid therapy:A meta-analysis of the randomized trails,1971-1994.Am J Obstet Gynecol 1995;173:322-335

9) Vigan'D PD, Blasio AM, et al:Danazol supresses both spotaneous and actived human lymphocyte-mediated cytotoxocity. Am J Reprod Immunol 1992;28-42

10) The recurrent miscarriage immunotherapy trialist group:Worldwide collaborative observational stududy and meta-analysis on allogenic leukocyte immunotherapy for recurrent spotaneous abortion.Am J Reprod Immunol 1994;32:55-72

P.456 掲載の参考文献

1) 世界保健機関(編)(武田文和, 訳): がんの痛みからの解放とパリアティブ・ケア. WHOテクニカル・レポート・シリーズ第804号. 1993, 金原出版, 東京

2) Twycross RA(武田文和, 訳): Palliative cancer care. JIM 1992; 2: 425-457

3) 世界保健機関(編)(武田文和, 訳): がんの痛みからの解放. WHO方式癌疼痛治療法, 第2版. 1996, 金原出版, 東京

4) 世界保健機関(編)(武田文和, 訳): 終末期の諸症状からの解放. 2000, 医学書院, 東京

5) 厚生省医薬安全局オピオイド研究会(監): 医療用麻薬の使用と管理'99/2000. 1999, ミクス, 東京

6) Twycross RA, Lack SA(武田文和, 訳): 末期癌患者の診療マニュアル, 第2版. 1991, 医学書院, 東京

P.464 掲載の参考文献

1) 長濱善夫: 薬物. 東洋医学概説. 1961; pp1-350, 創光社, 大阪

2) 楊育周: 傷寒六経病変. 1992; pp1-589, 人民衛生出版社, 北京

3) 日本漢方医学研究所: 総論. 漢方医学. 1990; pp17-71, 自然と科学社, 東京

4) 玉舎輝彦: 産婦人科漢方療法. 産婦人科薬物療法のすべて. 1996; pp135-160, 金芳堂, 京都

5) 玉舎輝彦: 更年期障害と漢方. 漢方と最新治療 1994; 3: 65-70

6) 玉舎輝彦: 産婦人科における補剤の活用. 漢方と最新治療 1999; 8: 175-183

7) 山田光胤, 丁宗鉄: 生薬ハンドブック. 1995; pp1-228, 協和企画, 東京

はじめての方へ

個人／法人会員登録のご案内